candesartan cilexetil profile

Candesartan cilexetil is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and heart failure. It works by blocking the effects of angiotensin II, a hormone that causes blood vessels to constrict. This helps to lower blood pressure and improve heart function. Candesartan cilexetil is synthesized through a multi-step process involving various chemical reactions. It was first synthesized in the late 1980s and has been extensively studied for its cardiovascular effects. The compound is important for treating high blood pressure and heart failure, as it has been shown to reduce the risk of heart attacks, strokes, and other cardiovascular events. It is studied to understand its long-term effects, optimize its dosage, and explore its potential uses in other cardiovascular conditions.'

candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2540
CHEMBL ID	1014
CHEBI ID	3348
SCHEMBL ID	40831
MeSH ID	M0208739

Synonym
AC-204
AB01274805-01
BRD-A65671304-001-02-6
r85m2x0d68 ,
unii-r85m2x0d68
nsc 758697
amias
h212/91
racanda
parapres
tcv-116
atacand
candesartan hexetil
kenzen
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate
SPECTRUM_001707
BSPBIO_002691
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)-1h-benzimidazole-7-carboxylate
1h-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-
candesartan cilexetil [usan]
tcv 116
1h-benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-
(+-)-1-hydroxyethyl 2-ethoxy-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
SPECTRUM5_001462
candesartan cilexetil
145040-37-5
C07709
DB00796
atacand (tn)
candesartan cilexetil (jp17/usp)
D00626
NCGC00095123-01
NCGC00095123-02
KBIOSS_002187
KBIO2_007323
KBIO2_004755
KBIO2_002187
KBIOGR_001607
KBIO3_001911
SPBIO_000349
SPECTRUM2_000485
SPECTRUM4_001124
SPECTRUM3_000996
SPECTRUM1504261
NCGC00095123-03
HMS2093E20
CHEMBL1014 ,
nsc-758697
candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester
chebi:3348 ,
L006257
HMS1922J09
bdbm50318907
2-ethoxy-3-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
candesartancilexetil
2-ethoxy-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
tox21_302202
NCGC00255218-01
cas-145040-37-5
dtxsid5020239 ,
dtxcid50239
nsc758697
BCP9000480
pharmakon1600-01504261
C2635
MLS004774127
smr003500784
AKOS015920180
candesartan cilexitil
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
CCG-39530
FT-0602914
AB07617
S2037
AKOS015894954
candesartan cilexetil [orange book]
candesartan cilexetil [jan]
candesartan cilexetil [vandf]
1h-benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+/-)-
candesartan cilexetil [ep monograph]
candesartan cilexetil [mart.]
candesartan cilexetil [who-dd]
(+/-)-1-hydroxyethyl 2-ethoxy-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester [mi]
candesartan cilexetil [usp monograph]
candesartan cilexetil [usp-rs]
CCG-222334
HY-17505
1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate
1h-benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
AM90293
SCHEMBL40831
KS-1147
1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7-carboxylate
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1h-tetrazol-5-yl) biphenyl-4-yl]methylbenzimidazole-7-carboxylate
GHOSNRCGJFBJIB-UHFFFAOYSA-N
1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate
Q-200786
camptothecine, antibiotic for culture media use only
candesartan cilextil
2-ethoxy-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
DS-1302
candesartan cilexetil, pharmaceutical secondary standard; certified reference material
gtpl8352
1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate
AB01274805_03
AB01274805_02
tcy 116
mfcd00871371
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate
STL451065
1261393-19-4
candesartan (cilexetil)
candesartan cilexetil , 97%
SR-05000001976-1
sr-05000001976
candesartan cilexetil, united states pharmacopeia (usp) reference standard
HMS3651I08
candesartan cilexetil, >=98% (hplc)
candesartan cilexetil for peak identification, european pharmacopoeia (ep) reference standard
candesartan cilexetil for system suitability, european pharmacopoeia (ep) reference standard
candesartan cilexetil, european pharmacopoeia (ep) reference standard
SBI-0206767.P001
1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl] methyl]benzimidazole-4-carboxylate
SW220041-1
NCGC00095123-05
BCP22050
candesartan cilexetil-d11
candesartan cilexetil (atacand)
Q27075664
BRD-A65671304-001-03-4
NCGC00095123-16
NCGC00095123-10
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate.
candesartan 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
candesartan celexetil ester
1-(((cyclohexyloxy)carbonyl)oxy)ethyl1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate
candesartan cilexetil- bio-x
BC164274
EN300-118698
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-1,3-benzodiazole-7-carboxylate
Z1515383338
SY051248
candesartan cilexetil (ep monograph)
candesartan cilexetil (usp monograph)
candesartan cilexetil (mart.)
candesartan cilexetil (usp-rs)
(+/-)1-hydroxyethyl 2-ethoxy-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)

Excerpt	Reference	Relevance
"Candesartan cilexetil is an angiotensin II receptor blocker and it is widely used to treat hypertension and heart failure. "	( Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Bae, JW; Cho, CK; Choi, CI; Jang, CG; Jung, EH; Kang, P; Lee, SY; Lee, YJ; Park, HJ, 2021)	2.06
"Candesartan cilexetil (CC) is a poorly soluble antihypertensive drug with "	( New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium. Alves, GF; Fernandes, D; França, MT; Leão, AF; Mendes, C; Pinto, JMO; Stulzer, HK, 2020)	2.22
"Candesartan cilexetil is a highly effective ARB for the treatment of arterial hypertension and heart failure. "	( Candesartan cilexetil: an update. Joost, A; Radke, PW; Schunkert, H, 2011)	3.25
"Candesartan cilexetil is a potent angiotensin receptor inhibitor with low bioavailability due to poor aqueous solubility. "	( Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Bu, H; Gao, F; Li, Y; Xiao, J; Zhang, Z, 2012)	2.1
"Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system."	( Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Cernes, R; Mashavi, M; Zimlichman, R, 2011)	1.09
"Candesartan cilexetil is a new angiotensin II receptor blocker with a high affinity for the angiotensin II-subtype 1 receptor."	( Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Matsumori, A, 2003)	2.06
"Candesartan cilexetil is an angiotensin II receptor antagonist that is widely used in the treatment of hypertension. "	( Erythema multiforme associated with candesartan cilexetil. Ejaz, AA; Walsh, JS; Wasiluk, A, 2004)	2.04
"Candesartan cilexetil is an angiotensin receptor blocker with insurmountable binding properties to the angiotensin-1 receptor, long duration of action and improved efficacy."	( Candesartan cilexetil in cardiovascular disease. Papademetriou, V; Ross, A, 2004)	2.49
"Candesartan cilexetil is a possible treatment for hypertension in renal allograft recipients. "	( Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Birkel, M; Kiel, G; Philipp, T; Pietruck, F; Stahlheber-Dilg, B, 2005)	2.07
"Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist. "	( Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension. Bönner, G; Fuchs, W, 2005)	2.04
"Candesartan cilexetil is an angiotensin receptor antagonist widely used in the treatment of high blood pressure. "	( Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure. Alonso, RM; Dresen, S; Ferreirós, N; Weinmann, W, 2007)	2.04
"Candesartan cilexetil is a novel AIIRA that has demonstrated clinical efficacy superior to losartan, has a sustained duration of action over 24 hours (trough:peak ratio close to 100%) and is well tolerated in patients with essential hypertension."	( Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. Sever, PS, 1999)	1.37
"Candesartan cilexetil is a potent and long-acting blocker that provides effective 24 hr blood pressure control."	( A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Kubo, K; Naka, T, 1999)	1.26
"Candesartan cilexetil is a potent and long-acting blocker that, when given once-daily to patients, provides effective 24 hr blood pressure control."	( A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Inada, Y; Kubo, K; Naka, T; Nishikawa, K, 1999)	1.26
"Candesartan cilexetil is an effective antihypertensive agent that can be used alone or in combination with other antihypertensive drugs."	( Candesartan cilexetil: an angiotensin II-receptor blocker. See, S; Stirling, AL, 2000)	2.47
"Candesartan cilexetil is a newly synthesized, specific angiotensin II type 1 receptor antagonist. "	( Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure. Yasue, H; Yoshimura, M, 2000)	1.99
"Candesartan cilexetil is a potent and long-acting blocker that, when given once a day to patients, provides effective 24 hr blood pressure control."	( [Angiotensin II receptor antagonists: candesartan cilexetil]. Furukawa, Y; Inada, Y; Kubo, K; Naka, T; Nishikawa, K, 2000)	1.3
"Candesartan cilexetil is an effective antihypertensive agent with a tolerability profile similar to that of placebo. "	( Candesartan cilexetil: an update of its use in essential hypertension. Easthope, SE; Jarvis, B, 2002)	3.2

Excerpt	Reference	Relevance
"Candesartan cilexetil has a rapid onset of action (approximately 80% of total blood pressure reduction within the first 2 weeks) and dose-dependent effects on blood pressure, is comparable in efficacy to a number of classes of antihypertensives, and is effective in combination therapy (eg, with hydrochlorothiazide and amlodipine)."	( Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. Sever, PS, 1999)	1.37
"Candesartan cilexetil has been shown to effectively reduce blood pressure and cardiovascular risk. "	( Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Bönner, G; Bramlage, P; Landers, B, 2011)	3.25
"Candesartan cilexetil has a rapid onset of action (approximately 80% of total blood pressure reduction within the first 2 weeks) and dose-dependent effects on blood pressure, is comparable in efficacy to a number of classes of antihypertensives, and is effective in combination therapy (eg, with hydrochlorothiazide and amlodipine)."	( Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. Sever, PS, 1999)	1.37
"Candesartan cilexetil has shown potent and long-lasting antihypertensive effects in clinical trials and in several animal models of hypertension. "	( Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action. Inada, Y; Kanagawa, R; Misumi, Y; Naka, T; Nishikawa, K; Ojima, M, 1999)	2.04
"Candesartan cilexetil has shown potent and long-lasting antihypertensive effects in clinical trials and in several hypertensive animal models. "	( [Pharmacological profiles of candesartan cilexetil (TCV-116)]. Inada, Y, 1999)	2.04
"Candesartan cilexetil has more than 1000 times more affinity for the angiotensin II, type AT1 receptor ARBs, and the binding affinity and competitive angiotensin II receptor antagonism is stronger than that of losartan."	( Candesartan cilexetil: an angiotensin II receptor blocker. Kaul, AF; McVoy, HJ; Stoukides, CA, 1999)	2.47
"Candesartan cilexetil has been found to produce a predictable and pronounced dose-dependent decrease in blood pressure, with placebo-like tolerability even at the highest doses studied."	( Improving antihypertensive efficacy while maintaining placebo-like tolerability. Sever, PS, 2000)	1.03
"Candesartan cilexetil has also been shown to be effective and well tolerated in combination with hydrochlorothiazide in those hypertensive patients who require more than one agent to reach their target blood pressure."	( Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade. Ruilope, L, 2000)	1.03

Excerpt	Reference	Relevance
"Candesartan cilexetil did not inhibit antigen-induced bronchoconstriction in sensitized guinea pigs or alter PC(200) in nonsensitized guinea pigs."	( Type 1 angiotensin II receptor antagonism reduces antigen-induced airway reactions. Fujimura, M; Hirose, T; Kurashima, K; Myou, S; Tachibana, H; Watanabe, K, 2000)	1.03

Excerpt	Reference	Relevance
"Candesartan cilexetil-treated banded rat hearts displayed shorter QT intervals and lower vulnerability to atrial and ventricular tachyarrhythmias than vehicle-treated banded hearts."	( Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction. Chang, GJ; Chen, WJ; Ko, YS; Lai, YJ; Lee, YS; Yeh, YH, 2022)	2.89
"Candesartan cilexetil treatment improved cardiac structural remodeling and cardiac function in SDT rats."	( Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S, 2009)	1.07
"Candesartan cilexetil treatments significantly reduced blood pressure (BP) in rats administered the high dose and moderately in rats receiving the low dose."	( Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011)	1.09
"The candesartan cilexetil-treated patients exhibited improvement of several aspects of QOL, including general symptoms, physical symptoms and well-being, work and satisfaction and sleep scale."	( The effects of replacing dihydropyridine calcium-channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients. Fujimoto, H; Kawashima, T; Koide, S; Kunitake, T; Yamamoto, S, 2003)	0.8
"Candesartan cilexetil is a possible treatment for hypertension in renal allograft recipients. "	( Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Birkel, M; Kiel, G; Philipp, T; Pietruck, F; Stahlheber-Dilg, B, 2005)	2.07
"Candesartan cilexetil treatment reduced neointimal formation both in allografts (Qint 30.2 +/- 8.8% vs."	( Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat. Fellström, B; Larsson, E; Zezina, L, 2001)	2.47
"Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction. "	( Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016)	1.18
"Treatment with candesartan cilexetil restored a normal pattern of reactivity in retinal capillaries (l-NMMA: decrease in perfusion by 10%+/-17%, P<0.05) and the central retinal artery (flicker: increase in mean blood flow velocity by 42%+/-31%, P<0.001) in hypertensive patients."	( Impaired endothelial function of the retinal vasculature in hypertensive patients. Delles, C; Harazny, J; Hilgers, KF; Michelson, G; Oehmer, S; Schmieder, RE, 2004)	0.66
"Treatment with candesartan cilexetil was initiated, and blood pressure control improved markedly."	( Erythema multiforme associated with candesartan cilexetil. Ejaz, AA; Walsh, JS; Wasiluk, A, 2004)	0.94
"Treatment with candesartan cilexetil lowered systemic blood pressure, normalized PGC at 10 weeks and greatly reduced proteinuria and allograft glomerulosclerosis at 24 weeks."	( Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats. Azuma, H; Brenner, BM; Mackenzie, HS; Nagano, H; Rennke, HG; Tilney, NL; Troy, JL; Ziai, F, 1997)	2.09
"Treatment with candesartan cilexetil caused significant decreases in blood pressure and amelioration of proteinuria and renal histological scores in the SHRSP/Izm rats."	( Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats. Nakaya, H; Saruta, T; Sasamura, H; Shimizu-Hirota, R, 2001)	0.65
"Oral treatment with candesartan cilexetil inhibited all central responses to i.c.v. "	( Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. Culman, J; Gohlke, P; Jürgensen, T; Kox, T; Rascher, W; Unger, T; Von Kügelgen, S, 2002)	0.94

Excerpt	Reference	Relevance
" In double-blind clinical trials in patients with primary hypertension, candesartan cilexetil 2-16 mg once-daily was associated with a low incidence of adverse events and drug-related withdrawals, similar to placebo."	( Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. Belcher, G; Elmfeldt, D; George, M; Hübner, R; Lunde, H, 1997)	1.97
" This pooled safety analysis was performed on adverse event data from five placebo-controlled studies involving a total of 1893 patients, 1287 of whom received candesartan cilexetil and 606 of whom received placebo."	( The safety and tolerability of candesartan cilexetil in CHF. Belcher, G; Erdmann, E; George, M; Held, P; Hiemstra, S; Kolb, D; Pietrek, M; Voet, B, 2000)	0.79
" To our knowledge, this is the first description of severe hepatotoxicity associated with ductopenia caused by an adverse reaction to candesartan cilexetil."	( Candesartan cilexetil-induced severe hepatotoxicity. Accetta, MG; Basile, G; Ferrara, T; Gangemi, S; Nicita-Mauro, V; Villari, D, 2003)	1.97
" Eight candesartan patients discontinued treatment because of an adverse event."	( Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. Hainer, JW; Radcliffe, J; Sorof, JM; Sugg, J; Teng, R; Trachtman, H, 2008)	0.61
" Candesartan was generally well tolerated; two patients withdrew for adverse events (fatigue and worsening glomerulopathy)."	( Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. Bagdasorova, IV; Drozdz, D; Gimpel, C; Hainer, JW; Montini, G; Schaefer, F; Sorof, J; Sugg, J; Teng, R; van de Walle, J; van Hoeck, K; Zurowska, A, 2010)	0.63
" Prolonged combined use of CC/PIO did not increase adverse events."	( Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. Enya, K; Kaku, K; Sugiura, K; Totsuka, N, 2011)	0.62
"from a total of 112 treatment-naive patients and 381 previously treated patients eligible for safety analysis, there were only 3 patients with adverse events, and 2 of which were considered possibly related to candesartan (0."	( Safety and effectiveness of candesartan and candesartan/HCT fixed dose combination in patients with hypertension. Pohan, T; Setiawati, A, 2013)	0.39
" Treatment with 10-mg azilsartan was similar to 8-mg candesartan cilexetil in its association with rare adverse events."	( Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. Arai, A; Kaneto, H; Katakami, N; Kusuda, Y; Matsuoka, TA; Shimomura, I; Shindo, M; Shiraiwa, T; Takahara, M, 2014)	0.9
" N/C combination demonstrated a lower incidence of vasodilatory adverse events than N monotherapy (18."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.4
"N/C combination was effective in participants with hypertension and showed an improved side effect profile compared with N monotherapy."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.4
" The primary assessment included the incidence of treatment-emergent adverse events (TEAEs)."	( Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. Dzongowski, P; Kjeldsen, SE; Li, N; Radlmaier, A; Wang, L, 2016)	0.66

Excerpt	Reference	Relevance
"The pharmacokinetic and pharmacodynamic properties of nonpeptide angiotensin antagonists in humans are reviewed in this paper."	( Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Biollaz, J; Brunner, HR; Buclin, T; Csajka, C, 1997)	0.3
" The AUC and Cmax of candesartan showed dose-proportional increases in the dose range of 2-16 mg candesartan cilexetil after both single and repeated once-daily tablet intake, indicating linear pharmacokinetics in both younger and elderly healthy subjects."	( Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. Högemann, AM; Hübner, R; Riddell, JG; Sunzel, M, 1997)	0.75
"The aim of this series of studies was to determine the potential for pharmacokinetic interaction between candesartan (administered orally as the prodrug candesartan cilexetil) and hydrochlorothiazide (HCTZ), nifedipine, glibenclamide, warfarin, digoxin or the components of an oral contraceptive formulation."	( Pharmacokinetic drug interaction studies with candesartan cilexetil. Högemann, A; Jonkman, JH; Lins, R; Sennewald, R; van Heiningen, PN; van Lier, JJ, 1997)	0.75
"Five clinical studies were conducted to investigate the pharmacokinetic profile and safety of candesartan cilexetil in patients with either normal or impaired renal or hepatic function."	( Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. de Zeeuw, D; Kirch, W; Remuzzi, G, 1997)	0.84
" From these model parameters, a cumulation half-life (t1/2, beta) of 29 h was derived."	( Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension--a population analysis. Feltkamp, H; Gundert-Remy, U; Högemann, A; Meineke, I, 1997)	0.52
"Although serum trough levels increased during repeated administration and half-life was higher in patients with impaired renal function, candesartan cilexetil at a dose of 8 mg per day does not lead to drug accumulation in these patients."	( Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Buter, H; de Jong, PE; de Zeeuw, D; Navis, GY; Woittiez, AJ, 1999)	0.77
"The pharmacokinetic profile of candesartan cilexetil might be altered in patients with end-stage renal disease (ESRD)."	( Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Frey, FJ; Pfister, M; Schaedeli, F; Uehlinger, DE, 1999)	0.86
"The pharmacodynamic effects of a single oral dose of 16 mg candesartan cilexetil are greater than those of 50 mg losartan and 8 mg candesartan cilexetil."	( Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. Azizi, M; Chatellier, G; Guyene, TT; Ménard, J, 1999)	0.8
" No relevant pharmacokinetic drug-food or drug-drug interactions are known."	( Clinical pharmacokinetics of candesartan. Gleiter, CH; Mörike, KE, 2002)	0.31
"This 4-week randomized, double blind, placebo-controlled study (N=240), 1-year open label trial (N=233), and single-dose pharmacokinetic study (N=22) evaluated candesartan cilexetil (3 doses) in hypertensive children aged 6 to 17 years."	( Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. Hainer, JW; Radcliffe, J; Sorof, JM; Sugg, J; Teng, R; Trachtman, H, 2008)	0.81
"A single-dose pharmacokinetic profile was obtained in 10 patients."	( Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. Bagdasorova, IV; Drozdz, D; Gimpel, C; Hainer, JW; Montini, G; Schaefer, F; Sorof, J; Sugg, J; Teng, R; van de Walle, J; van Hoeck, K; Zurowska, A, 2010)	0.63
"There was no pharmacokinetic interaction between candesartan 32 mg and HCT 25 mg during concomitant administration."	( Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide. Aberg, JG; Karlson, BW; Olofsson, B, 2011)	0.6
"There was no pharmacokinetic interaction found between the high doses of candesartan 32 mg and HCT 25 mg."	( Pharmacokinetic interaction study with fixed high dose combinations of candesartan cilexetil and hydrochlorothiazide. Aberg, JG; Karlson, BW; Olofsson, B, 2011)	0.6
" The method uses 100 µl plasma and covers the calibration range 1-160 ng/ml for CAN and 2-160 ng/ml for HCTZ for routine pharmacokinetic studies in humans."	( LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. Bharathi, DV; Chatki, PK; Hotha, KK; Satyanarayana, V; Venkateswarlu, V, 2012)	0.38
" The developed assay was applied to an oral pharmacokinetic study in humans."	( LC-MS/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics. Bharathi, DV; Chatki, PK; Hotha, KK; Satyanarayana, V; Venkateswarlu, V, 2012)	0.38
" The pharmacokinetic parameters such as AUC(last), AUC(inf) and C(max) were calculated and the 90% confidence intervals of the ratio (test/reference) pharmacokinetic parameters were obtained by analysis of variance on logarithmically transformed data."	( Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers. Chae, SW; Cho, BS; Choi, YH; Han, SM; Im, YJ; Jang, HY; Jeon, JY; Jo, MJ; Kim, BK; Kim, MG; Kim, Y; Lee, BH; Moon, BK; Shin, DH; Yoo, JS, 2013)	0.64
" The physicochemical properties, morphology of CC-SLNs were characterized, the pharmacokinetic and pharmacodynamic behaviour of CC-SLNs were evaluated in rats."	( Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Dudhipala, N; Veerabrahma, K, 2016)	1.88
"This study was performed to compare the single-dose pharmacokinetic properties and tolerability of DP-R208 (candesartan and rosuvastatin FDC) to those of each component administered alone in healthy Korean male volunteers."	( Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects . Jang, K; Jeon, JY; Kim, MG; Lee, BH; Lee, JW; Park, CW; Park, DB, 2017)	0.7
" We investigated the effect of genetic polymorphism of CYP2C9 enzyme on drug pharmacokinetics using physiologically based pharmacokinetic (PBPK) modeling."	( Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Bae, JW; Cho, CK; Choi, CI; Jang, CG; Jung, EH; Kang, P; Lee, SY; Lee, YJ; Park, HJ, 2021)	0.62
"To evaluate if the combination of the product components in the new FDC capsule formulation affects their respective pharmacokinetic and in vitro dissolution patterns."	( Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects. Diaz, L; Feleder, EC; Haddad, T; Halabe, EK; Iglesias, M; Mondelo, N; Roldán, E; Sakson, M; Yerino, GA, 2022)	0.97

Excerpt	Reference	Relevance
" Candesartan cilexetil was well tolerated both alone and in combination with the other agents."	( Pharmacokinetic drug interaction studies with candesartan cilexetil. Högemann, A; Jonkman, JH; Lins, R; Sennewald, R; van Heiningen, PN; van Lier, JJ, 1997)	1.47
"To compare candesartan cilexetil and lisinopril in fixed combination with hydrochlorothiazide with respect to antihypertensive efficacy and tolerability."	( Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. Istad, H; Keinänen-Kiukaanniemi, S; McInnes, GT; O'Kane, KP; Van Mierlo, HF, 2000)	0.96
"This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension."	( Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000)	0.94

Excerpt	Reference	Relevance
"In order to improve the oral bioavailability (BA) of 2-butyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimid azole - 7-carboxylic acid (3: CV-11194) and 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (4: CV-11974), novel angiotensin II (AII) receptor antagonists, chemical modification to yield prodrugs has been examined."	( Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. Furukawa, Y; Inada, Y; Kato, T; Kohara, Y; Kubo, K; Naka, T; Nishikawa, K; Shibouta, Y; Yoshimura, Y, 1993)	0.29
" Co-administration of candesartan cilexetil with HCTZ produced a statistically significant increase in the bioavailability and Cmax values for candesartan (18% and 25%, respectively)."	( Pharmacokinetic drug interaction studies with candesartan cilexetil. Högemann, A; Jonkman, JH; Lins, R; Sennewald, R; van Heiningen, PN; van Lier, JJ, 1997)	0.87
" To improve bioavailability (BA) of candesartan, chemical modification was examined to yield candesartan cilexetil, a prodrug of candesartan."	( A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Kubo, K; Naka, T, 1999)	0.76
" To improve bioavailability of candesartan, chemical modification was examined to yield candesartan cilexetil, a prodrug of candesartan."	( A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Inada, Y; Kubo, K; Naka, T; Nishikawa, K, 1999)	0.76
" To improve bioavailability of candesartan, chemical modification was examined to yield candesartan cilexetil, a prodrug of candesartan."	( [Angiotensin II receptor antagonists: candesartan cilexetil]. Furukawa, Y; Inada, Y; Kubo, K; Naka, T; Nishikawa, K, 2000)	0.8
" Oral bioavailability is low (about 40%) because of incomplete absorption."	( Clinical pharmacokinetics of candesartan. Gleiter, CH; Mörike, KE, 2002)	0.31
" In human umbilical endothelial cells, candesartan increased the eNOS protein level AT2-R dependently, inhibited the expression of nicotinamide adenine dinucleotide phosphate oxidase subunits and angiotensin II-induced intracellular reactive oxygen species and nitric oxide, and promoted the extracellular release of nitric oxide, suggesting that it augmented the bioavailability of nitric oxide."	( Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies. Kanematsu, Y; Kinouchi, T; Kitazato, KT; Liu, H; Nagahiro, S; Tada, Y; Tamura, T; Uno, M; Yagi, K, 2008)	0.35
" The objective of the present study was to develop a tablet dosage form of candesartan cilexetil incorporating drug nanoparticles to increase its saturation solubility and dissolution rate for enhancing bioavailability while reducing variability in systemic exposure."	( Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Harisudhan, T; Nekkanti, V; Pillai, R; Venkateshwarlu, V, 2009)	0.58
" These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2."	( Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010)	0.36
" However, CC exhibited incomplete intestinal absorption with low oral bioavailability due to its poor aqueous solubility."	( Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. Bu, H; Gao, F; Gao, Z; Huang, Y; Li, Y; Shen, J; Zhang, Z; Zhao, C, 2011)	0.63
"The poor solubility and wettability of Candesartan cilexetil (CAN) leads to poor dissolution and hence, low bioavailability after oral administration."	( Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions. Avachat, AM; Shaikh, SM, 2011)	0.9
" The pharmacokinetic results indicated that the oral bioavailability of candesartan was obviously improved over 12-fold after incorporation into solid lipid nanoparticles."	( Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Bu, H; Gao, F; Li, Y; Xiao, J; Zhang, Z, 2012)	0.66
"Candesartan cilexetil is a potent angiotensin receptor inhibitor with low bioavailability due to poor aqueous solubility."	( Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Bu, H; Gao, F; Li, Y; Xiao, J; Zhang, Z, 2012)	2.1
" It was thus expected that Fujicalin and Neusilin UFL2-based bi-layer SMET would overcome low oral bioavailability of CDC due to its limited solubility at physiological pH conditions in the gastrointestinal tract."	( Development of self-microemulsifying bilayer tablets for pH-independent fast release of candesartan cilexetil. Kim, SY; Kuh, HJ; Lee, BJ; Lee, GH; Lee, J; Lee, SY; Na, YJ; Seong, I; Sohn, Y, 2012)	0.6
"The present study was conducted to compare the bioavailability of two candesartan cilexetil 16 mg tablet formulations (test and reference formulations)."	( Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions. Santoso, ID; Setiawati, E; Simanjuntak, R; Susanto, LW; Tjandrawinata, RR; Yunaidi, DA, 2013)	0.88
"7-folds increase in apparent bioavailability was noticed with freeze-dried solid dispersions with naringin as compared to free CAN suspension administered alone."	( Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor. Gurunath, S; Nanjwade, BK; Patil, PA, 2015)	0.67
"This study demonstrated that increased solubilization (favored by freeze-dried solid dispersion) and efflux pump inhibition (using naringin), the relative bioavailability of CDS can be increased, suggesting an alternative potential for improving oral bioavailability of CAN."	( Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models. K Nanjwade, B; Patil, PA; Surampalli, G, 2015)	0.64
" The in vivo pharmacokinetic study gave many folds increase in oral bioavailability than CC suspension, which was further confirmed by antihypertensive activity in a murine model."	( Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation. Ahmad, FJ; Ali, A; Fazil, M; Hafeez, A; Imam, SS; Khan, S; Paudel, A, 2017)	0.74
"Candesartan cilexetil (CC), an antihypertensive drug, has low oral bioavailability due to poor solubility and hepatic first-pass metabolism."	( Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability. Dudhipala, N; Veerabrahma, K, 2017)	3.34
"Candesertan cilexetil is a Biopharmaceutics Classification System (BCS) Class II drug possessing high permeability but low aqueous solubility; hence its oral bioavailability is limited in terms of the solubility rate."	( DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL. Nalbantoglu, A; Sengel-Turk, CT; Ugurlu, T, 2016)	0.43
" The human absolute bioavailability reported demonstrates that candesartan cilexetil has low permeability and when associated with the low solubility allows to classify it as class 4 of the Biopharmaceutics Classification System."	( Polymorphic and Quantum Chemistry Characterization of Candesartan Cilexetil: Importance for the Correct Drug Classification According to Biopharmaceutics Classification System. da Nova Mussel, W; de Campos, DP; de Souza, J; Lima, RR; Savedra, RML; Silva-Barcellos, NM; Siqueira, MF; Yoshida, MI, 2018)	0.97
"The drug delivery of candesartan cilexetil encounters an obstacle of low absolute oral bioavailability which is attributed mainly to its low aqueous solubility and efflux by intestinal P-glycoprotein (P-gp) transporters."	( A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation. AboulFotouh, K; Allam, AA; El-Badry, M; El-Sayed, AM, 2019)	1.06
"The objective of this study was to compare different techniques to enhance the solubility and dissolution rate, and hence the bioavailability of candesartan cilexetil."	( Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. Ali, TFS; Aly, UF; Sarhan, HA; Sharkawy, HAE, 2020)	1
" Following the preparations, all samples were characterized for their physicochemical properties, and the samples of the best results were subjected to further bioavailability studies."	( Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. Ali, TFS; Aly, UF; Sarhan, HA; Sharkawy, HAE, 2020)	0.8
" Results showed a significant increase in the bioavailability of CC from ~15% to ~48%."	( Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. Ali, TFS; Aly, UF; Sarhan, HA; Sharkawy, HAE, 2020)	0.8
"The bioavailability of CC was significantly improved from ~15% to ~48% when formulated as SDs with PVP K-90 with 1:4 drug:polymer ratio."	( Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug. Ali, TFS; Aly, UF; Sarhan, HA; Sharkawy, HAE, 2020)	0.8
"Candesartan cilexetil (CC), a prodrug of candesartan (CDT), is a class II BCS drug that suffers from poor oral bioavailability because of low aqueous solubility, P-gp efflux and first-pass metabolism."	( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats. AbuElfadl, A; Boughdady, M; Meshali, M, 2021)	2.31
" The synergistic combination of Peceol™ and Span™ 60 probably surmounted the P-gp efflux with an increase in oral absolute bioavailability of niosomes to five times that of CC suspension."	( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats. AbuElfadl, A; Boughdady, M; Meshali, M, 2021)	0.87
"The new niosomal formulations of CC containing Peceol™ with Span™ 60 and cholesterol either uncoated or coated with chitosan were a successful paradigm in achieving high oral absolute bioavailability and increased Caco-2 cells biocompatibility."	( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats. AbuElfadl, A; Boughdady, M; Meshali, M, 2021)	0.87

Excerpt	Relevance	Reference
" The characterisation of their pharmacokinetic-pharmacodynamic relationships deserves further refinement for designing optimal therapeutic regimens and proposing dosage adaptations in specific conditions."	( Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Biollaz, J; Brunner, HR; Buclin, T; Csajka, C, 1997)	0.3
"A high incidence of maternal toxicity in rabbits characterized by uremia and death was observed when TCV-116, a novel angiotensin II subtype-1 (AT1) receptor antagonist, was orally administered to pregnant rabbits at dosage levels of 3 mg/kg/day or more."	( Characterization of the high sensitivity of rabbits to the effects of TCV-116, an angiotensin II receptor antagonist. Chatani, F; Ito, K; Kito, G; Sato, K, 1997)	0.3
" Frequent blood samples were collected after the first single dose of candesartan cilexetil, and during the last dosing interval after 1 week repeated once-daily administration."	( Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. Högemann, AM; Hübner, R; Riddell, JG; Sunzel, M, 1997)	0.77
" In order to delineate the dose-response curve for candesartan cilexetil (the orally administered prodrug), results from six European placebo-controlled, dose-response studies were pooled."	( Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. Elmfeldt, D; George, M; Hübner, R; Olofsson, B, 1997)	1.99
" When administered in a flexible dosage regimen of 4-16 mg once-daily, candesartan cilexetil effectively lowered blood pressure (BP) and maintained its antihypertensive effects over the long term (< or =12 months)."	( Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. Holzgreve, H; Sever, P, 1997)	0.8
" The usual maintenance doses of candesartan cilexetil are expected to be 8 mg and 16 mg once-daily and dosage adjustment does not appear to be necessary in elderly patients or those with mild to moderate renal or hepatic impairment."	( Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. Sever, P, 1997)	2.02
", candesartan shifted the dose-response curve to angiotensin II to the right in a nonparallel manner, suggesting a noncompetitive blockade."	( Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat. Champion, HC; Kadowitz, PJ; Lambert, DG, 1998)	0.3
" Before and up to 24 h post dosing angiotensin II was infused in ascending dose steps until blood pressure (systolic and/or diastolic) increased by +25 mmHg."	( Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, B; Herrmann, V; Högemann, A; Magin, SG; Malerczyk, C; Mutschler, E; Roll, S; Voith, B, 1998)	0.3
" DR at 6-9 h post dosing reached a maximum of about 30 and at 24 h still amounted to 4-7, indicating the persistence of a relevant antagonistic effect in vivo."	( Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, B; Herrmann, V; Högemann, A; Magin, SG; Malerczyk, C; Mutschler, E; Roll, S; Voith, B, 1998)	0.3
" In the TCV-116 group, the erythrocyte count, hematocrit value and hemoglobin concentration were decreased by 7-8% as compared with the values in the control group after dosing for 28 days."	( Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Chatani, F; Naeshiro, I; Sato, K; Sato, S, 1998)	0.56
" In addition, endothelium-dependent and endothelium-independent relaxation was evaluated by dose-response curves to acetylcholine (in the presence or absence of a bradykinin-receptor blocker and of indomethacin) and sodium nitroprusside."	( Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. Bettoni, G; Castellano, M; Guelfi, D; Muiesan, ML; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D; Rosei, EA, 1998)	0.69
"At 2, 3 h and 4 h after dosing with candesartan cilexetil, systolic blood pressure (SBP) and DBP, as well as mean arterial pressure (MAP), were significantly lower than at baseline."	( Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Andersson, OK; Friberg, P; Fridman, K; Sunzel, M; Wysocki, M, 1998)	0.91
" No such correlation was detected for each single dose of candesartan cilexetil but a dose-response relationship was present when both doses were combined."	( Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. Azizi, M; Chatellier, G; Guyene, TT; Ménard, J, 1999)	0.8
" A dose-response curve to norepinephrine was performed at cumulative concentrations in the presence or absence of low- and high-dose insulin."	( High-dose, not low-dose insulin increases the vasoconstrictor effect of norepinephrine in spontaneously hypertensive rats: effects of antihypertensive treatment. Castellano, M; Guelfi, D; Muiesan, ML; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D; Rosei, EA, )	0.13
" In these studies, ambulatory blood pressure monitoring is continued throughout the dosing interval and beyond in order to determine when systolic and diastolic blood pressure increase into the hypertensive range."	( Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999)	0.53
"The purpose of this double-blind, forced titration study was to compare the antihypertensive effect duration of candesartan cilexetil, which has a longlasting binding to the human AT1-receptor, to that of losartan on ambulatory BP (ABP) not only during the 24-h dosing interval but also during the day of a missed dose intake."	( A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Lo Asmar, R; Lacourcière, Y, 1999)	0.76
" Dosage adjustments are not necessary in elderly patients or in patients with mild hepatic or renal dysfunction."	( Candesartan cilexetil: an angiotensin II receptor blocker. Kaul, AF; McVoy, HJ; Stoukides, CA, 1999)	1.75
" Each drug effectively lowers blood pressure during once daily administration to patients with mild to moderate hypertension, with candesartan cilexetil requiring the lowest dosage and providing dose-dependent efficacy."	( Newly emerging pharmacologic differences in angiotensin II receptor blockers. Oparil, S, 2000)	0.51
" The initial dosage of candesartan was 4 mg/d; the dosage was increased to 16 mg/d if the drug was tolerated."	( Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Bart, BA; Califf, RM; Ertl, G; Granger, CB; Held, P; Kuch, J; Maggioni, AP; McMurray, J; Michelson, EL; Ohlin, G; Pfeffer, MA; Rouleau, JL; Sellers, MA; Sparapani, R; Stevenson, LW; Swedberg, K; Young, J; Yusuf, S, 2000)	0.63
" Observed trough-to-peak blood pressure ratios support a once-daily dosage regimen."	( Candesartan cilexetil: an angiotensin II-receptor blocker. See, S; Stirling, AL, 2000)	1.75
"5% 2 h after dosing with 8 mg of candesartan cilexetil."	( Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure. Yasue, H; Yoshimura, M, 2000)	0.82
" The trough-to-peak ratio is a useful measure of the persistence of antihypertensive efficacy at the end of the dosing interval."	( Achieving quality 24-h blood pressure control with candesartan cilexetil. Meredith, P, 2000)	0.56
" Oral dosing of L-NAME (100 mg/kg per day) for 7 days significantly raised plasma fibrinogen concentration in rats."	( Effect of prolonged nitric oxide synthesis inhibition on plasma fibrinogen concentration in rats. Fujimura, A; Sugimoto, K; Tsuruoka, S, 2001)	0.31
" In both treatment groups the dosage could be doubled after > or =2 weeks [according to blood pressure (BP) response] and, if necessary, subsequently decreased if the higher dosage was poorly tolerated."	( Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Forsén, B; Neldam, S, 2001)	0.52
"Lack of efficacy in the treatment of hypertension with only one drug presents a problem in general practice and often requires switching to another type of drug, because higher dosage of currently used antihypertensives increases the frequency of side effects."	( [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)]. Baumgart, P; Düsing, R; Pohlmeyer, H; Reismann, J, 2001)	0.55
"In order to investigate the role of Angiotensin II (AII) for the vasogenic cerebral edema, the AT1 receptor antagonist (TCV-116) was administered to 19-week-old stroke-prone spontaneously hypertensive rats (SHRSP) for 2 weeks at a dosage which did not decrease the blood pressure."	( AT1 receptor antagonist prevents brain edema without lowering blood pressure. Ito, H; Kawai, J; Suzuki, T; Takemori, K, 2000)	0.31
" The response rate of monotherapy with candesartan in patients with hypertension increases with dosage, but never exceeds 60% at a daily dosage of 16mg of candesartan."	( Clinical pharmacokinetics of candesartan. Gleiter, CH; Mörike, KE, 2002)	0.31
" Angiotensin II (Ang II) antagonistic effects were determined in vivo from rightward shifts in Ang II dose-response curves for diastolic blood pressure (BP) and dose ratios were calculated."	( The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man. Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, W; Hausdorf, C; Mang, C, 2000)	0.31
" Significant reductions in systolic BP and diastolic BP are achieved with a once-daily dosage of candesartan cilexetil 2 to 32 mg/day in patients with mild to moderate hypertension."	( Candesartan cilexetil: an update of its use in essential hypertension. Easthope, SE; Jarvis, B, 2002)	1.97
"A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis."	( Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. Abe, K; Arakawa, M; Kikkawa, R; Kurokawa, K; Ogawa, N; Onoyama, K; Saruta, T; Tomita, K; Ueda, N, 2002)	0.82
" Good linearity, precision and selectivity were found, and the two methods were successfully applied to the pharmaceutical dosage form containing the above-mentioned drug combination without any interference by the excipients."	( Application of first derivative UV-spectrophotometry and ratio derivative spectrophotometry for the simultaneous determination of candesartan cilexetil and hydrochlorothiazide. Erk, N, 2003)	0.52
" The experiment protocol included sham-operated rats (Sham), MI-control rats (MI-control), MI rats treated with ramipril 3 mg/kg (MI-ramipril) or TCV116 2 mg/kg (MI-TCV116) per day, half dosage (MI-1/2R&T) or full dosage (MI-R&T) combination of the two."	( Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction. Huang, YW; Tao, ZW; Xia, Q; Xu, QW, 2005)	0.33
"The results suggest that treatment with appropriate dosage combination of a chronic ACEI and a chronic ARB may further improve cardiac remodeling and cardiac function after MI."	( Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction. Huang, YW; Tao, ZW; Xia, Q; Xu, QW, 2005)	0.33
"Both candesartan and valsartan similarly alter taste sensitivity after the repeated dosing of the drug."	( Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. Ando, H; Fujimura, A; Ioka, T; Sugimoto, K; Tsuruoka, S; Wakaumi, M; Yamamoto, H, 2005)	0.33
"Twenty-four-hour ambulatory blood pressure monitoring (ABPM) provides the most accurate efficacy assessment of an antihypertensive agent throughout a 24-hour dosing interval."	( A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Alegría, E; Gonzalez-Juanatey, JR; Marquez, E; Olivan, J; Palma-Gamiz, JL; Pêgo, M; Pujol, M; Sagastagoitia-Gorostiza, JD, 2007)	0.6
"Imidapril in once-daily doses of up to 20mg was shown to be at least as effective as candesartan cilexetil given in once-daily doses of up to 16 mg in reducing BP throughout the entire 24-hour dosing interval."	( A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Alegría, E; Gonzalez-Juanatey, JR; Marquez, E; Olivan, J; Palma-Gamiz, JL; Pêgo, M; Pujol, M; Sagastagoitia-Gorostiza, JD, 2007)	0.82
" All of these were similar in design: i) a 4-week placebo run-in period, ii) a 4- to 6-week period (V1) with CC 8 mg once daily (od), after which the dosage was doubled if BP was not normalized (BP > 140/90 or BP >130/80 mmHg in diabetes), and iii) a 4- to 6-week period (V2) with CC 8 or 16 mg od."	( Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. Asmar, R; Féghali, RE; Nisse-Durgeat, S, 2007)	0.74
" Depending on the BP response, dosage of CC 8 mg was doubled at the follow-up visit if BP >or=140/90 mmHg."	( [Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes]. Asmar, R; El Féghali, R; Nisse-Durgeat, S, 2007)	0.71
" Patients underwent a 7-day washout period prior to initiation of weight-based dosing of candesartan cilexetil (2-8 mg daily)."	( Candesartan cilexetil effectively reduces blood pressure in hypertensive children. Franks, AM; Gardner, SF; O'Brien, CE; Stowe, CD; Wells, TG, 2008)	2.01
" RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm."	( A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008)	0.35
" The objective of the present study was to develop a tablet dosage form of candesartan cilexetil incorporating drug nanoparticles to increase its saturation solubility and dissolution rate for enhancing bioavailability while reducing variability in systemic exposure."	( Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Harisudhan, T; Nekkanti, V; Pillai, R; Venkateshwarlu, V, 2009)	0.58
" Candesartan was uptitrated to 32 mg/day (target dose if tolerated) during 6 weeks followed by constant dosing over 16 weeks."	( Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice. Appel, KF; Dereli, S; Hamm, CW; Mitrovic, V; Proskynitopoulos, N, 2009)	0.74
" After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12."	( Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009)	0.74
"3%, thus a flow-through dissolution apparatus was recommended for testing prolonged release dosage forms."	( The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media. Hoppe, K; Sznitowska, M, 2014)	0.64
"DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) aimed to determine the dose-response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.59
" A positive dose-response was observed, with all combinations providing statistically better blood pressure (BP) reductions from baseline versus respective monotherapies (P < 0."	( Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014)	0.4
"To ensure safe oral administration, pediatric patients require an appropriate dosage form to be swallowed without relevant difficulties."	( Choice of excipients for gelly-like pulp prepared ex tempore "on a spoon"- "placebo" and with sartans. Boniecka, M; Kluk, A; Sznitowska, M; Wolska, E; Zarazińska, M, 2016)	0.43
" A trend to dose-response relationship was observed in each subgroup."	( Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses. Cha, G; Kjeldsen, SE; Mancia, G; Villa, G, 2016)	0.43
" The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension."	( Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. Ahn, T; Chae, SC; Cho, EJ; Cho, JH; Choi, JY; Chung, WB; Hong, TJ; Ihm, SH; Jeon, HK; Jeong, MH; Kim, CJ; Kim, WS; Kim, YK; Lee, HY; Lee, JH; Nam, CW; Park, JI; Park, SM; Shin, ES; Sohn, IS; Yang, TH; Yoon, JH; Youn, HJ, 2017)	0.68
" In addition, by introducing the age and ethnicity into the model, we developed a model that can propose an appropriate dosage regimen taking into account the individual characteristics of each patient."	( Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Bae, JW; Cho, CK; Choi, CI; Jang, CG; Jung, EH; Kang, P; Lee, SY; Lee, YJ; Park, HJ, 2021)	0.62

Class	Description
biphenyls	Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	39.8107	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	39.8107	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	31.6228	0.1778	14.3909	39.8107	AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	28.1838	0.1259	19.1169	125.8920	AID2549
Chain A, Cruzipain	Trypanosoma cruzi	Potency	10.2175	0.0020	14.6779	39.8107	AID1476; AID1478
Luciferase	Photinus pyralis (common eastern firefly)	Potency	56.3719	0.0072	15.7588	89.3584	AID1224835
acetylcholinesterase	Homo sapiens (human)	Potency	70.9680	0.0025	41.7960	15,848.9004	AID1347397
15-lipoxygenase, partial	Homo sapiens (human)	Potency	31.6228	0.0126	10.6917	88.5700	AID887
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	42.3981	3.1890	29.8841	59.4836	AID1224846; AID1224894
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	22.5363	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	17.3647	0.1737	34.3047	61.8120	AID1346859; AID1346924
USP1 protein, partial	Homo sapiens (human)	Potency	22.3872	0.0316	37.5844	354.8130	AID504865
SMAD family member 3	Homo sapiens (human)	Potency	17.3647	0.1737	34.3047	61.8120	AID1346859; AID1346924
TDP1 protein	Homo sapiens (human)	Potency	26.1011	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	25.0112	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	30.6626	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	54.4372	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	10.8617	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	52.4639	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	29.3319	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	2.3919	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	44.1759	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	47.1602	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	30.2730	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	43.5417	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	43.6181	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	24.3162	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	45.9944	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079
G	Vesicular stomatitis virus	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	13.4504	0.0010	8.3798	61.1304	AID1645840
glucocerebrosidase	Homo sapiens (human)	Potency	0.1122	0.0126	8.1569	44.6684	AID2101
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	23.3530	0.0010	19.4141	70.9645	AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	8.7154	0.0237	23.2282	63.5986	AID743222; AID743223; AID743241
caspase-3	Homo sapiens (human)	Potency	54.4372	0.0133	26.9810	70.7614	AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	48.5172	0.0017	23.8393	78.1014	AID743083
activating transcription factor 6	Homo sapiens (human)	Potency	48.9403	0.1434	27.6121	59.8106	AID1159516; AID1159519
thyrotropin-releasing hormone receptor	Homo sapiens (human)	Potency	19.0137	0.1549	17.8702	43.6557	AID1346877
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	42.0996	19.7391	45.9784	64.9432	AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	29.9395	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	44.9805	0.0391	47.5451	146.8240	AID1224845; AID1224896
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	43.2410	0.0067	23.4960	68.5896	AID1346980
hemoglobin subunit beta	Homo sapiens (human)	Potency	19.9526	0.3162	9.0861	31.6228	AID910
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	25.1189	0.3162	12.4435	31.6228	AID902; AID924
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	31.6228	0.0018	15.6638	39.8107	AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	44.6684	0.3548	28.0659	89.1251	AID504847
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	43.2410	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	23.8328	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	38.8747	0.0420	27.3789	61.6448	AID743210; AID743228
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	35.4813	0.0398	16.7842	39.8107	AID1454
ubiquitin carboxyl-terminal hydrolase 2 isoform a	Homo sapiens (human)	Potency	0.7943	0.6561	9.4520	25.1189	AID927
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	31.2781	0.0006	27.2152	1,122.0200	AID743202; AID743219
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	24.7028	0.0079	8.2332	1,122.0200	AID2546; AID2551
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	28.1838	0.0316	22.3146	100.0000	AID588579
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	12.5893	0.0316	10.2792	39.8107	AID884; AID885
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	19.9526	0.2512	15.8432	39.8107	AID504327
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	25.1189	0.3162	12.7657	31.6228	AID881
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	61.0796	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	4.7724	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	24.6374	0.0023	19.5956	74.0614	AID651631; AID720552
Integrin beta-3	Homo sapiens (human)	Potency	25.1189	0.3162	11.4157	31.6228	AID924
Integrin alpha-IIb	Homo sapiens (human)	Potency	25.1189	0.3162	11.4157	31.6228	AID924
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	61.0796	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	25.1189	0.0063	8.2350	39.8107	AID881
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)	Potency	0.7943	1.5849	13.0043	25.1189	AID927
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	12.5893	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cruzipain	Trypanosoma cruzi	IC50 (µMol)	105.0000	0.0002	2.0450	8.0000	AID484274; AID484275
Type-1 angiotensin II receptor	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	0.2000	0.0001	0.0913	0.5000	AID568911
NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)	IC50 (µMol)	16.4300	0.0003	0.0471	0.1800	AID1728035
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	IC50 (µMol)	2.4547	0.1047	2.7195	7.0795	AID977603
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Ki	1.9000	0.0800	2.4688	9.8000	AID977604
DNA polymerase kappa	Homo sapiens (human)	IC50 (µMol)	7.4000	3.4000	5.9500	9.2000	AID1315755; AID1315756
DNA polymerase iota	Homo sapiens (human)	IC50 (µMol)	6.2000	0.0620	2.1123	6.2000	AID1315759
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	5.0000	0.0040	1.9666	10.0000	AID1873191
DNA polymerase eta	Homo sapiens (human)	IC50 (µMol)	11.2000	0.0620	0.0685	0.0750	AID1315758
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	IC50 (µMol)	0.7244	0.0500	2.3797	9.7000	AID977600
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	Ki	0.4000	0.0440	1.3630	5.0000	AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)	EC50 (µMol)	4.2000	0.0000	0.9922	10.0000	AID1737435
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activity	Integrin beta-3	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
cell-substrate junction assembly	Integrin beta-3	Homo sapiens (human)
cell adhesion	Integrin beta-3	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
embryo implantation	Integrin beta-3	Homo sapiens (human)
blood coagulation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of gene expression	Integrin beta-3	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid storage	Integrin beta-3	Homo sapiens (human)
response to activity	Integrin beta-3	Homo sapiens (human)
smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
platelet activation	Integrin beta-3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-3	Homo sapiens (human)
activation of protein kinase activity	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid transport	Integrin beta-3	Homo sapiens (human)
regulation of protein localization	Integrin beta-3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Integrin beta-3	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin beta-3	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
tube development	Integrin beta-3	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-3	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Integrin beta-3	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
wound healing	Integrin beta-3	Homo sapiens (human)
apoptotic cell clearance	Integrin beta-3	Homo sapiens (human)
regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-3	Homo sapiens (human)
positive regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast proliferation	Integrin beta-3	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Integrin beta-3	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin beta-3	Homo sapiens (human)
negative chemotaxis	Integrin beta-3	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Integrin beta-3	Homo sapiens (human)
regulation of serotonin uptake	Integrin beta-3	Homo sapiens (human)
angiogenesis involved in wound healing	Integrin beta-3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Integrin beta-3	Homo sapiens (human)
platelet aggregation	Integrin beta-3	Homo sapiens (human)
cellular response to mechanical stimulus	Integrin beta-3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Integrin beta-3	Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferation	Integrin beta-3	Homo sapiens (human)
blood coagulation, fibrin clot formation	Integrin beta-3	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trapping	Integrin beta-3	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
regulation of trophoblast cell migration	Integrin beta-3	Homo sapiens (human)
regulation of extracellular matrix organization	Integrin beta-3	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Integrin beta-3	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Integrin beta-3	Homo sapiens (human)
positive regulation of T cell migration	Integrin beta-3	Homo sapiens (human)
cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of leukocyte migration	Integrin alpha-IIb	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-IIb	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-IIb	Homo sapiens (human)
angiogenesis	Integrin alpha-IIb	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-IIb	Homo sapiens (human)
negative regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of cholesterol efflux	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
long-chain fatty acid transport	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of osteoblast differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of receptor signaling pathway via STAT	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of low-density lipoprotein receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of signaling receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of BMP signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of MAP kinase activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of adiponectin secretion	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stress	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healing	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
placenta development	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
signal transduction	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
response to nutrient	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of blood pressure	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of gene expression	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
macrophage derived foam cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cholesterol storage	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of lipid storage	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of sequestering of triglyceride	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of angiogenesis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
monocyte differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
BMP signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
epithelial cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to insulin stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
response to lipid	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
peroxisome proliferator activated receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
glucose homeostasis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of circadian rhythm	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipoprotein transport	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
innate immune response	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell fate commitment	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of fat cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
retinoic acid receptor signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell maturation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
rhythmic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
white fat cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
lipid homeostasis	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of SMAD protein signal transduction	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of cholesterol transporter activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cellular response to hypoxia	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of mitochondrial fission	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
regulation of cellular response to insulin stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of extracellular matrix assembly	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of miRNA transcription	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of adipose tissue development	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of vascular endothelial cell proliferation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of fatty acid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
fatty acid metabolic process	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
negative regulation of inflammatory response	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cell differentiation	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
hormone-mediated signaling pathway	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to hypoxia	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
neutrophil mediated immunity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
germinal center formation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of leukocyte chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane protein ectodomain proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch receptor processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell population proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to xenobiotic stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of T cell chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
signal release	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
B cell differentiation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell growth	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to lipopolysaccharide	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of chemokine production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
regulation of mast cell apoptotic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
T cell differentiation in thymus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion mediated by integrin	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
wound healing, spreading of epidermal cells	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
spleen development	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell motility	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
defense response to Gram-positive bacterium	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cellular response to high density lipoprotein particle stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
commissural neuron axon guidance	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
signal transduction	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
mitotic DNA replication checkpoint signaling	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
regulation of apoptotic process	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
regulation of neuron apoptotic process	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein neddylation	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
neuron apoptotic process	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein ubiquitination	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
DNA damage response	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
proteolysis	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
endomitotic cell cycle	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein modification process	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
post-translational protein modification	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein neddylation	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
regulation of cell cycle	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
DNA replication	DNA polymerase kappa	Homo sapiens (human)
DNA repair	DNA polymerase kappa	Homo sapiens (human)
nucleotide-excision repair, DNA gap filling	DNA polymerase kappa	Homo sapiens (human)
DNA damage response	DNA polymerase kappa	Homo sapiens (human)
cellular response to UV	DNA polymerase kappa	Homo sapiens (human)
error-prone translesion synthesis	DNA polymerase kappa	Homo sapiens (human)
DNA replication	DNA polymerase iota	Homo sapiens (human)
DNA repair	DNA polymerase iota	Homo sapiens (human)
error-prone translesion synthesis	DNA polymerase iota	Homo sapiens (human)
translesion synthesis	DNA polymerase iota	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
DNA synthesis involved in DNA repair	DNA polymerase eta	Homo sapiens (human)
DNA replication	DNA polymerase eta	Homo sapiens (human)
DNA repair	DNA polymerase eta	Homo sapiens (human)
regulation of DNA repair	DNA polymerase eta	Homo sapiens (human)
pyrimidine dimer repair	DNA polymerase eta	Homo sapiens (human)
response to UV-C	DNA polymerase eta	Homo sapiens (human)
error-free translesion synthesis	DNA polymerase eta	Homo sapiens (human)
cellular response to UV-C	DNA polymerase eta	Homo sapiens (human)
response to radiation	DNA polymerase eta	Homo sapiens (human)
error-prone translesion synthesis	DNA polymerase eta	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast growth factor binding	Integrin beta-3	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-3	Homo sapiens (human)
insulin-like growth factor I binding	Integrin beta-3	Homo sapiens (human)
neuregulin binding	Integrin beta-3	Homo sapiens (human)
virus receptor activity	Integrin beta-3	Homo sapiens (human)
fibronectin binding	Integrin beta-3	Homo sapiens (human)
protease binding	Integrin beta-3	Homo sapiens (human)
protein disulfide isomerase activity	Integrin beta-3	Homo sapiens (human)
protein kinase C binding	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor binding	Integrin beta-3	Homo sapiens (human)
integrin binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin beta-3	Homo sapiens (human)
coreceptor activity	Integrin beta-3	Homo sapiens (human)
enzyme binding	Integrin beta-3	Homo sapiens (human)
identical protein binding	Integrin beta-3	Homo sapiens (human)
vascular endothelial growth factor receptor 2 binding	Integrin beta-3	Homo sapiens (human)
metal ion binding	Integrin beta-3	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-3	Homo sapiens (human)
extracellular matrix binding	Integrin beta-3	Homo sapiens (human)
fibrinogen binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin alpha-IIb	Homo sapiens (human)
identical protein binding	Integrin alpha-IIb	Homo sapiens (human)
metal ion binding	Integrin alpha-IIb	Homo sapiens (human)
extracellular matrix binding	Integrin alpha-IIb	Homo sapiens (human)
molecular adaptor activity	Integrin alpha-IIb	Homo sapiens (human)
fibrinogen binding	Integrin alpha-IIb	Homo sapiens (human)
integrin binding	Integrin alpha-IIb	Homo sapiens (human)
transcription cis-regulatory region binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
transcription coregulator binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleic acid binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
chromatin binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
double-stranded DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nuclear receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
prostaglandin receptor activity	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
zinc ion binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
enzyme binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
peptide binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
identical protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
sequence-specific DNA binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nuclear retinoid X receptor binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
arachidonic acid binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA binding domain binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
LBD domain binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
alpha-actinin binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
R-SMAD binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
E-box binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
STAT family protein binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription factor binding	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
endopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
interleukin-6 receptor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
integrin binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
peptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metallopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
SH3 domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytokine binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
PDZ domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
tumor necrosis factor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metal ion binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
NEDD8 activating enzyme activity	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein binding	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
ubiquitin protein ligase binding	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein heterodimerization activity	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
ubiquitin activating enzyme activity	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
NEDD8 activating enzyme activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein binding	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
ATP binding	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
NEDD8 activating enzyme activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
NEDD8 transferase activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
identical protein binding	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein heterodimerization activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
damaged DNA binding	DNA polymerase kappa	Homo sapiens (human)
metal ion binding	DNA polymerase kappa	Homo sapiens (human)
DNA-directed DNA polymerase activity	DNA polymerase kappa	Homo sapiens (human)
damaged DNA binding	DNA polymerase iota	Homo sapiens (human)
DNA-directed DNA polymerase activity	DNA polymerase iota	Homo sapiens (human)
protein binding	DNA polymerase iota	Homo sapiens (human)
metal ion binding	DNA polymerase iota	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
damaged DNA binding	DNA polymerase eta	Homo sapiens (human)
DNA-directed DNA polymerase activity	DNA polymerase eta	Homo sapiens (human)
protein binding	DNA polymerase eta	Homo sapiens (human)
metal ion binding	DNA polymerase eta	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
glutamatergic synapse	Integrin beta-3	Homo sapiens (human)
nucleus	Integrin beta-3	Homo sapiens (human)
nucleoplasm	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin beta-3	Homo sapiens (human)
cell-cell junction	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
external side of plasma membrane	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
apical plasma membrane	Integrin beta-3	Homo sapiens (human)
platelet alpha granule membrane	Integrin beta-3	Homo sapiens (human)
lamellipodium membrane	Integrin beta-3	Homo sapiens (human)
filopodium membrane	Integrin beta-3	Homo sapiens (human)
microvillus membrane	Integrin beta-3	Homo sapiens (human)
ruffle membrane	Integrin beta-3	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin beta-3	Homo sapiens (human)
melanosome	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
postsynaptic membrane	Integrin beta-3	Homo sapiens (human)
extracellular exosome	Integrin beta-3	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin beta-3	Homo sapiens (human)
glycinergic synapse	Integrin beta-3	Homo sapiens (human)
integrin complex	Integrin beta-3	Homo sapiens (human)
protein-containing complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin beta-3	Homo sapiens (human)
receptor complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-vitronectin complex	Integrin beta-3	Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complex	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
focal adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell surface	Integrin alpha-IIb	Homo sapiens (human)
platelet alpha granule membrane	Integrin alpha-IIb	Homo sapiens (human)
extracellular exosome	Integrin alpha-IIb	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin alpha-IIb	Homo sapiens (human)
blood microparticle	Integrin alpha-IIb	Homo sapiens (human)
integrin complex	Integrin alpha-IIb	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nucleus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleus	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
nucleoplasm	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
cytosol	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
intracellular membrane-bounded organelle	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
chromatin	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
receptor complex	Peroxisome proliferator-activated receptor gamma	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
cell-cell junction	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
focal adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
ruffle membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Golgi membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytoplasm	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
endoplasmic reticulum lumen	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytosol	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell surface	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
actin cytoskeleton	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
apical plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane raft	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytosol	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
plasma membrane	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein-containing complex	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
cytoplasm	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
nucleus	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
nucleus	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
cytosol	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein-containing complex	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
cytoplasm	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
nucleus	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
site of DNA damage	DNA polymerase kappa	Homo sapiens (human)
nucleus	DNA polymerase kappa	Homo sapiens (human)
nucleoplasm	DNA polymerase kappa	Homo sapiens (human)
nuclear body	DNA polymerase kappa	Homo sapiens (human)
nucleus	DNA polymerase kappa	Homo sapiens (human)
nucleoplasm	DNA polymerase iota	Homo sapiens (human)
nuclear speck	DNA polymerase iota	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	DNA polymerase iota	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
nucleoplasm	DNA polymerase eta	Homo sapiens (human)
cytosol	DNA polymerase eta	Homo sapiens (human)
nucleus	DNA polymerase eta	Homo sapiens (human)
replication fork	DNA polymerase eta	Homo sapiens (human)
site of double-strand break	DNA polymerase eta	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID749449	Inhibition of Hepatitis C virus CON1 NS5B RNA dependent RNA polymerase after 2 hrs by scintillation counting analysis	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine learning methods.
AID1519950	Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 75 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 63.84 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID183922	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 5 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1519984	Induction of apoptosis in human A549 cells assessed as increase in PARP cleavage at 50 to 100 uM by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1315759	Inhibition of human DNA polymerase iota preincubated for 15 mins followed by replicating non-damaged DNA substrate addition measured after 30 mins in presence of dCTP and dGTP by radioactive gel-based primer extension assay	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.
AID1519924	Antiproliferative activity against human HepG2 cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519966	Binding affinity to biotin-labeled GST-tagged NAE (unknown origin) incubated for 1 hr by SPR assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1737435	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as intrinsic activity measured after 39 hrs by dual luciferase reporter assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID183920	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 24 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1519996	Antitumor activity against human A549 cells xenografted in nude mouse assessed as decrease in tumor weight at 30 mg/kg, ip qd measured after 22 days	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID183923	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 7 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1728034	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation at 100 uM incubated for 48 hrs by CCK-8 assay relative to control	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID26234	Bioavailability determined from the ratio of AUC(plasma) for 0 to infinity after oral dosing of the test compound (10 mg/kg) to intravenous administration of CD-11194 (1 mg/kg) in rats	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1519991	Competitive inhibition of Nedd8-Ubc12 (unknown origin) adduct formation assessed as decrease in Ubc12-Nedd8 adduct formation at 50 uM preincubated for 10 mins followed by ATP addition and measured after 30 mins by immunoblot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID484275	Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in presence of 0.01% Triton X-100	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1519956	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 50 uM measured after 48 hrs by AnnexinV-FITC/propidium iodide staining based FACS analysis (Rvb = 2.19 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519952	Cell cycle arrest in human A549 cells assessed as accumulation at G2 phase at 75 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 12.69 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519987	Antitumor activity against human A549 cells xenografted in nude mouse assessed as decrease in tumor size at 60 mg/kg, ip qd measured after 22 days	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID568922	Antihypertensive activity in po dosed conscious rat	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1519967	Antiproliferative activity against human A549 cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519993	Inhibition of cullin-RING ligase in human A549 cells assessed as accumulation of p27 level at 50 to 125 uM and measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID183921	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 3 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1519953	Cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 75 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 0.89 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1737443	Cytotoxicity against human HS5 cells assessed as cell death at 10 uM measured after 72 hrs by Propidium iodide stain based FACS analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1519947	Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 50 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 21.54 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1728036	Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID1519946	Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 50 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 63.84 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519970	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin3-Nedd8 adduct level at 50 uM measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1315755	Inhibition of human DNA polymerase kappa (19 to 526 residues) preincubated for 15 mins followed by replicating non-damaged DNA substrate addition measured after 30 mins in presence of dCTP and dGTP by radioactive gel-based primer extension assay	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.
AID484277	Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 0.25% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1728033	Inhibition of NAE (unknown origin)-mediated neddylation assessed as suppression of cullin1-Nedd8 adduct formation at 25 uM preincubated for 10 mins followed by ATP addition and measured after 30 mins by immunoblot analysis relative to control	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID484297	Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 550 uM by dynamic light scattering assay in presence of 1% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1519955	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 25 uM measured after 48 hrs by AnnexinV-FITC/propidium iodide staining based FACS analysis (Rvb = 1.71 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519942	Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 25 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 63.84 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519973	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin1-Nedd8 adduct level measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519945	Cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 25 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 0.89 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID27680	Tested for Half- life in rat liver homogenate (2%)	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1315756	Inhibition of human DNA polymerase kappa (19 to 526 residues)-mediated TLS past acrolein derived ring-opened reduced form of gamma-HOPdG lesions preincubated for 15 mins followed by DNA substrate addition measured after 30 mins in presence of dCTP and dGT	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.
AID1519951	Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 75 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 21.54 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID183919	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 2 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID39653	Relative binding affinity of compound to Angiotensin II receptor, type 1 was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1519929	Antiproliferative activity against human MGC803 cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1728035	Inhibition of NAE (unknown origin)-mediated neddylation assessed as suppression of cullin1-Nedd8 adduct formation preincubated for 10 mins followed by ATP addition and measured after 30 mins by immunoblot analysis	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID1737437	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 20 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID484274	Inhibition of Trypanosoma cruzi cruzaine preincubated for 5 mins before substrate addition by fluorescence assay in absence of Triton X-100	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1737436	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 10 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1728038	Cytotoxicity against human 16H6E cells incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID1519948	Cell cycle arrest in human A549 cells assessed as accumulation at G2 phase at 50 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 12.69 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519962	Inhibition of Nedd8-cullin1 (unknown origin) assessed as decrease in cullin1-Nedd8 adduct formation at 25 to 50 uM preincubated for 10 mins followed by ATP addition and measured after 30 mins by immunoblot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519923	Antiproliferative activity against human H1299 cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519965	Competitive inhibition of Nedd8-cullin1 (unknown origin) adduct formation at 12.5 to 50 uM assessed as increase in substrate Km by Lineweaver-Burk plot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519969	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin2-Nedd8 adduct level at 50 uM measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID484380	Colloidal aggregation in fed state simulated intestinal fluid assessed as colloid radius at 50 uM by dynamic light scattering assay in presence of 1% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID27681	Tested for Half- life in rat plasma homogenate (10%) at 37 degree Centigrade	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1737434	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as maximal activation at 10 uM measured after 39 hrs by dual luciferase reporter assay relative to pioglitazo	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID977603	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1519930	Antiproliferative activity against human PLC cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID18418	Oral bioavailability was evaluated in rat; Range is 28-33 %	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1519931	Cytotoxicity against human BEAS2B cells after 48 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519976	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin4a-Nedd8 adduct level measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519963	Inhibition of Nedd8-Ubc12 (unknown origin) assessed as decrease in Ubc12-Nedd8 adduct formation at 50 uM preincubated for 10 mins followed by ATP addition and measured after 30 mins by immunoblot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1873191	Inhibition of human ABCG2 expressed in dog MDCK-II-BCRP cells mediated pheophorbide A efflux and measured after 60 mins using pheophorbide A as fluorescent substrate by flow cytometry	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1519922	Antiproliferative activity against human EKVX cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519957	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 50 uM measured after 48 hrs by AnnexinV-FITC/propidium iodide staining based FACS analysis (Rvb = 1.71 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519994	Effect on Ub-modified protein level in human A549 cells by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID484296	Colloidal aggregation in fed state simulated intestinal fluid by dynamic light scattering assay in presence of 2.75% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1519932	Cytotoxicity against human 16HBE cells after 48 hrs by CCK-8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519990	Competitive inhibition of Nedd8-cullin1 (unknown origin) adduct formation assessed as decrease in cullin1-Nedd8 adduct formation at 50 uM preincubated for 10 mins followed by ATP addition and measured after 30 mins by immunoblot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519968	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin1-Nedd8 adduct level at 50 uM measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519954	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 25 uM measured after 48 hrs by AnnexinV-FITC/propidium iodide staining based FACS analysis (Rvb = 2.19 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519975	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin3-Nedd8 adduct level measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1519979	Inhibition of UbcH10 in human A549 cells assessed as reduction in protein ubiquitination by measuring Ubc10-ub adduct formation at 50 to 100 uM by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519927	Antiproliferative activity against human MCF7 cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519986	Antitumor activity against human A549 cells xenografted in nude mouse assessed as decrease in tumor weight at 60 mg/kg, ip qd measured after 22 days	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519972	Inhibition of UBE2F in human A549 cells assessed as decrease in Cullin5-Nedd8 adduct level at 50 uM measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID679592	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Candesartan cilexetil: 50 uM) in MDR1-expressing LLC-PK1 cells	2002	Life sciences, Feb-15, Volume: 70, Issue:13	Interaction of digoxin with antihypertensive drugs via MDR1.
AID568869	Oral bioavailability in rat	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID484392	Colloidal aggregation in fed state simulated intestinal fluid at 550 uM by dynamic light scattering-based beads autocorrelation assay in presence of 2.75% DMSO	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Colloid formation by drugs in simulated intestinal fluid.
AID1519978	Inhibition of Ubc9 in human A549 cells assessed as reduction in protein sumoylation by measuring Ubc9-Sumo adduct formation at 50 to 100 uM by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID977604	Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID184050	Inhibitory activity on AII (100 ng/kg iv)-induced pressor response at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 1 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID26947	Total oral bioavailability was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1519980	Effect on SUMO1 level in human A549 cells by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519988	Toxicity in nude mouse xenografted with human A549 cells assessed as effect on body weight at 30 to 60 mg/kg, ip qd measured every 2 days	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1728053	Toxicity in nude mouse assessed as effect on body weight at 30 mg/kg, qd after 24 days	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID1519926	Antiproliferative activity against human T47D cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519958	Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 75 uM measured after 48 hrs by AnnexinV-FITC/propidium iodide staining based FACS analysis (Rvb = 2.19 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID27685	Tested for half- life in rat small intestine homogenate (1%)	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1519997	Antitumor activity against human A549 cells xenografted in nude mouse assessed as decrease in tumor size at 30 mg/kg, ip qd measured after 22 days	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519925	Antiproliferative activity against human HuH7 cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519971	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin4a-Nedd8 adduct level at 50 uM measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID568911	Antagonist activity at angiotensin AT1 receptor in rabbit aortic strip assessed as inhibition of angiotensin 2-induced contractile response	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1519974	Inhibition of UBC12 in human A549 cells assessed as decrease in Cullin2-Nedd8 adduct level measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1519928	Antiproliferative activity against human MKN45 cells measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519943	Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 25 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 21.54 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID176435	Oral effective dose required for inhibition of Ang II pressor response in rats	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1519985	Inhibition of colony formation in human A549 cells measured after 10 days	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519960	Inhibition of Nedd8-cullin1 (unknown origin) adduct formation assessed as decrease in cullin1 neddylation at 50 uM preincubated for 10 mins followed by ATP addition and measured after 30 mins by immunoblot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519959	Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 75 uM measured after 48 hrs by AnnexinV-FITC/propidium iodide staining based FACS analysis (Rvb = 1.71 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID977601	Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1519992	Inhibition of cullin-RING ligase in human A549 cells assessed as accumulation of Wee1 level at 50 to 125 uM and measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519977	Inhibition of UBE2F in human A549 cells assessed as decrease in Cullin5-Nedd8 adduct level measured after 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1728039	Cytotoxicity against human BEAS-2B cells incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID1519949	Cell cycle arrest in human A549 cells assessed as accumulation at sub-G1 phase at 50 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 0.89 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1728037	Antiproliferative activity against human H1299 cells incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.
AID1315758	Inhibition of human DNA polymerase eta (1 to 437 residues) preincubated for 15 mins followed by replicating non-damaged DNA substrate addition measured after 30 mins in presence of dCTP and dGTP by radioactive gel-based primer extension assay	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.
AID1519961	Inhibition of Nedd8-cullin1 adduct formation in human A549 cells assessed as decrease in cullin1 neddylation at 100 uM incubated for 6 to 12 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1519964	Competitive inhibition of Nedd8-cullin1 (unknown origin) adduct formation at 12.5 to 50 uM assessed as substrate Vmax by Lineweaver-Burk plot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID977600	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1519944	Cell cycle arrest in human A549 cells assessed as accumulation at G2 phase at 25 uM measured after 24 hrs by propidium iodide/RNase A staining based flow cytometry analysis (Rvb = 12.69 %)	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID184209	Inhibitory effect on AII (100 ng/kg iv)-induced pressor response after administration at 0.1 mg/kg po in conscious male Sprague-Dawley rats at 0.5 h.	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158	ZIKV-mCherry secondary qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170	Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172	Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156	DAPI mCherry counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171	Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	208 (34.38)	18.2507
2000's	248 (40.99)	29.6817
2010's	127 (20.99)	24.3611
2020's	22 (3.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	151 (24.04%)	5.53%
Reviews	94 (14.97%)	6.00%
Case Studies	10 (1.59%)	4.05%
Observational	6 (0.96%)	0.25%
Other	367 (58.44%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (158)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension [NCT01289132]	Phase 2	926 participants (Actual)	Interventional	2007-07-31	Completed
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke [NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C [NCT03770936]	Phase 3	45 participants (Anticipated)	Interventional	2018-10-01	Recruiting
Influence of Blockade of the Renin-angiotensin System for Preservation of Cognitive Function, Hormonal Counter-regulatory Response, Symptomatology and Cardiac Repolarisation During Hypoglycaemia in Patients With Type 1 Diabetes [NCT01116180]		9 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb) [NCT01135212]	Phase 3	290 participants (Actual)	Interventional	2010-04-30	Completed
A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled [NCT02368665]	Phase 3	180 participants (Actual)	Interventional	2014-12-31	Completed
A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled [NCT02368652]	Phase 3	181 participants (Actual)	Interventional	2014-12-31	Completed
Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation [NCT01162902]	Phase 4	150 participants (Anticipated)	Interventional	2013-09-30	Not yet recruiting
Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence [NCT01227603]	Phase 1	49 participants (Actual)	Interventional	2010-11-30	Completed
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers [NCT02646982]	Phase 2	77 participants (Actual)	Interventional	2016-06-30	Completed
Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan and the Loose Combination of Both Components and to Investigate the Bioequivalence Between the Fixed [NCT01350609]	Phase 1	49 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Amlodipine Between Free Combination of Amlodipine and Candesartan and Amlodipine Monotherapy in Healthy Male Volunteers [NCT02064556]	Phase 1	24 participants (Actual)	Interventional	2014-05-31	Completed
A Randomized, Double-blind, Multi-center, PhaseⅡ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Candesartan Cilexetil and Amlodipine Besylate for the Dose Selection in Patients With Essential Hypertension [NCT02059616]	Phase 2	384 participants (Anticipated)	Interventional	2014-02-28	Recruiting
An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Candesartan 32 mg and Rosuvastatin 20 mg in Healthy Male Volunteers [NCT02079506]	Phase 1	40 participants (Actual)	Interventional	2014-02-28	Completed
Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomize [NCT03136666]	Phase 1	12 participants (Actual)	Interventional	2010-04-19	Completed
DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy. [NCT00252720]	Phase 3	1,850 participants (Actual)	Interventional	2001-08-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control [NCT02521233]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Refe [NCT02094924]	Phase 1	16 participants (Actual)	Interventional	2014-04-17	Completed
The Effect of Continuing or Discontinuing ACE-I/ARBs Therapy on the Incidence of Contrast-induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Coronary Angiography; a Randomized Controlled Trial [NCT05271448]		600 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02186496]	Phase 1	32 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Candesartan Between Free Combination of Candesartan and Amlodipine and Candesartan Monotherapy in Healthy Male Volunteers [NCT02064621]	Phase 1	24 participants (Actual)	Interventional	2014-06-30	Completed
Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety Following Administration of CJ-30059 and Co-administration of Candesartan Cilexetil and Amlodipine Besylate in Healthy Volunteers. [NCT02173912]	Phase 1	32 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) [NCT00081731]	Phase 3	947 participants (Actual)	Interventional	2004-04-30	Completed
Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function [NCT00634400]	Phase 3	6,268 participants (Anticipated)	Interventional	1999-03-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control [NCT02521246]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI. [NCT01052272]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2005-07-31	Completed
A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension [NCT01025843]	Phase 1	20 participants (Actual)	Interventional	2009-12-01	Completed
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02801526]	Phase 1	32 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets [NCT03847506]	Phase 4	127 participants (Actual)	Interventional	2018-07-05	Completed
A Randomized, Double-blind, Multi-center, Phase 2 Trial to Evaluate the Efficacy and Safety of Candesartan/Amlodipine Combined or Alone and Select Better Dose of CKD-330 in Patients With Essential Hypertension [NCT02206165]	Phase 2	456 participants (Anticipated)	Interventional	2014-03-31	Recruiting
A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients With Essential Hypertension [NCT01303783]	Phase 2	1,381 participants (Actual)	Interventional	2011-04-30	Completed
An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Cande [NCT02254447]	Phase 1	18 participants (Actual)	Interventional	2014-12-02	Completed
A Multicenter, Double-blind, Controlled, Randomized Trial to Evaluate the Association Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension [NCT05920005]	Phase 3	698 participants (Anticipated)	Interventional	2023-08-22	Recruiting
Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension [NCT01012479]	Phase 4	107 participants (Actual)	Interventional	2009-10-31	Completed
Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight [NCT04002440]		28 participants (Actual)	Interventional	2018-11-08	Active, not recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
The Precision Hypertension Care Study [NCT02774460]	Phase 4	280 participants (Actual)	Interventional	2017-02-20	Completed
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function [NCT00634712]	Phase 3	734 participants (Anticipated)	Interventional	1999-06-30	Completed
A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R208 (Candesartan Cilexetil and Rosuvastatin Calcium Fixed Dose Combinations) in Comparison to Each Component Administered Alone in Healthy Male Volunteers [NCT02707224]	Phase 1	40 participants (Actual)	Interventional	2015-01-31	Completed
Randomized, Controlled, Parallel Arm, PROBE Study to Evaluate Different Effects of Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension [NCT00644475]	Phase 3	60 participants (Anticipated)	Interventional	2008-03-31	Recruiting
CandeSpartan Study Candesartan Spanish Response-prediction and Tolerability Study Observational Study on Response Predictors and Tolerability of Candesartan in Usual Clinical Practice [NCT04138316]		85 participants (Actual)	Observational [Patient Registry]	2020-01-02	Completed
"A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a Real-liFe GP sEtting in Sweden" [NCT00620178]		14,000 participants (Anticipated)	Observational	2008-03-31	Completed
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers [NCT02811731]	Phase 1	32 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy [NCT02651870]	Phase 3	135 participants (Actual)	Interventional	2015-04-22	Completed
A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HC [NCT00434967]	Phase 3	2,207 participants (Actual)	Interventional	2007-01-31	Completed
Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study [NCT00884663]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2009-04-30	Completed
A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA) [NCT03640312]	Phase 2	62 participants (Actual)	Interventional	2019-08-30	Active, not recruiting
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine in a Combination Package Compared to the Separate Intake of the Reference Brands Atacand and Splendil After a Fasting Period. [NCT00905333]	Phase 1	36 participants (Actual)	Interventional	2008-10-31	Completed
Angiotensin Receptor Blockade an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C [NCT00930995]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Not Awarded)
Single Dose Crossover Comparative Bioavailability Study of Candesartan Cilexetil 32 mg Tablets in Healthy Adult Subjects Under Fasting Conditions [NCT04012307]	Phase 1	40 participants (Actual)	Interventional	2019-07-11	Completed
Does Telmisartan Compared to Candesartan Due to a Distinctly Larger Volume of Distribution Exert Stronger Effects in Relevant Peripheral Tissues, e.g. Renal and Adrenal Tissues [NCT02261116]	Phase 4	24 participants (Actual)	Interventional	2002-04-30	Completed
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV) [NCT00679484]	Phase 3	400 participants (Anticipated)	Interventional	2008-06-30	Terminated(stopped due to Lack of subject recruitment)
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France [NCT00679640]		450 participants (Actual)	Observational	2008-01-31	Completed
[NCT02614352]	Phase 1	60 participants (Anticipated)	Interventional		Not yet recruiting
The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves [NCT00699452]	Phase 3	120 participants (Anticipated)	Interventional	2009-05-31	Recruiting
[NCT02609711]	Phase 1	90 participants (Anticipated)	Interventional	2015-11-30	Active, not recruiting
"Candesartan Added Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Inv [NCT00775840]	Phase 3	22 participants (Actual)	Interventional	2008-01-31	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
A Single Dose, 2-Period, Cross-over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil [NCT00844324]	Phase 1	36 participants (Actual)	Interventional	2009-03-31	Completed
Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function [NCT00843154]	Phase 3	571 participants (Actual)	Interventional	2005-12-31	Terminated(stopped due to Insufficient enrollment)
Effects of Telmisartan Compared With Candesartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients: a Multi-center, Prospective, Randomized, Open-labeled, Blinded Endpoints Trial [NCT00863980]		1,500 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Principle investigator resigned in 2013)
A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy [NCT00573430]	Phase 4	128 participants (Actual)	Interventional	2007-12-31	Completed
Open Label, Comparative, Multiple-dose, Fixed-sequence Steady State Trial in Healthy Volunteers to Assess the Pharmacokinetic Interaction of Candesartan, Atorvastatin and Amlodipine After a Multiple Oral Dose Administration [NCT04245046]	Phase 1	18 participants (Actual)	Interventional	2019-01-18	Completed
An Open-label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: a Long Term Study [NCT00690612]	Phase 3	35 participants (Actual)	Interventional	2007-09-30	Completed
Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 m [NCT00621153]	Phase 4	214 participants (Actual)	Interventional	2008-02-29	Completed
Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine [NCT00564057]	Phase 4	30 participants (Anticipated)	Interventional	2007-09-30	Recruiting
Double-blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous ß-blocker or Calcium Channel Blocker [NCT00775814]	Phase 4	188 participants (Actual)	Interventional	2006-10-31	Completed
A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects With Essential Hypertension Who Are Inadequately Co [NCT02047019]	Phase 3	0 participants (Actual)	Interventional	2017-12-01	Withdrawn(stopped due to GPDC decided to terminate the study)
Bariatric Surgery and Pharmacokinetics Candesartan: BAR-MEDS Candesartan [NCT03460327]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy. [NCT00252733]	Phase 3	5,238 participants (Actual)	Interventional	2001-06-30	Completed
Characterization of Vascular Effects of Candesartan and Pioglitazone. [NCT00154037]		40 participants	Interventional	2005-10-31	Completed
Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1) [NCT00538486]	Phase 4	360 participants (Actual)	Interventional	2008-02-29	Completed
Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy. [NCT00252694]	Phase 3	4,717 participants (Actual)	Interventional	2001-08-31	Completed
A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy [NCT00348686]	Phase 4	315 participants (Actual)	Interventional	2006-06-30	Completed
A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to S [NCT00242346]	Phase 3	270 participants	Interventional	2003-04-30	Completed
An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 8mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 8mg Reference Tablet of Candesartan Cilexetil (Atacand) in He [NCT02006589]	Phase 1	16 participants (Actual)	Interventional	2013-12-11	Completed
An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 16mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 16mg Reference Tablet of Candesartan Cilexetil (Atacand) in [NCT02006602]	Phase 1	16 participants (Actual)	Interventional	2013-12-13	Completed
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? [NCT04606563]	Phase 3	341 participants (Actual)	Interventional	2020-10-09	Terminated(stopped due to DSMC recommendation due to futility)
Open Label, Randomized, Active Drug Comparative, Parallel Group, Multi-center, Phase IV Study to Compare and Evaluate the Efficacy and Safety of Candemore Tab and Atacand Tab. [NCT01682564]	Phase 4	169 participants (Actual)	Interventional	2012-01-31	Completed
Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial [NCT00990639]	Phase 1/Phase 2	85 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunt [NCT02548286]	Phase 1	53 participants (Actual)	Interventional	2015-08-31	Completed
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia. [NCT02770261]	Phase 3	219 participants (Actual)	Interventional	2015-12-31	Completed
DP-R208 Pharmacokinetic Study Phase I [NCT02709187]	Phase 1	37 participants (Actual)	Interventional	2016-03-31	Completed
The Renin-angiotensin System (RAS) in Barrett's Esophagus as Future Biomarkers for Dysplasia and Cancer? A Randomized Controlled Trial [NCT02879721]	Early Phase 1	33 participants (Actual)	Interventional	2009-10-31	Completed
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function [NCT00634309]	Phase 3	597 participants (Anticipated)	Interventional	1999-06-30	Completed
Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients [NCT00541853]	Phase 4	150 participants (Anticipated)	Interventional	2007-12-31	Not yet recruiting
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothi [NCT00867490]	Phase 3	186 participants (Actual)	Interventional	2009-03-31	Completed
Angiotensin-II Blockade in Mitral Regurgitation [NCT00587470]	Phase 4	60 participants (Actual)	Interventional	1998-08-31	Completed
A Phase-3 Randomized, Double-Blind, Parallel-Group Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine (8/5 mg) in Chinese Subjects With Mild/Moderate Essential Hypertension, Who Do Not Achieve Target Blood Press [NCT02969265]	Phase 3	0 participants (Actual)	Interventional	2017-05-09	Withdrawn(stopped due to Business reasons unrelated to product safety)
ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs [NCT00192803]	Phase 4	20 participants	Interventional		Not yet recruiting
Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab [NCT00459771]	Phase 3	210 participants (Actual)	Interventional	2007-06-30	Completed
Heart Outcomes Prevention Evaluation-3 [NCT00468923]	Phase 4	12,705 participants (Actual)	Interventional	2007-05-31	Completed
Genetic Epidemiology of Responses to Antihypertensives [NCT00005520]		1,200 participants (Actual)	Observational	1997-02-28	Completed
Neurohumoral and Oxidative Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Essential Hypertensive Patients. [NCT00232882]	Phase 4	86 participants (Actual)	Interventional	2003-12-31	Completed
A 36 Week Three-Center Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo [NCT00282178]	Phase 2	26 participants (Actual)	Interventional	2005-04-30	Completed
Scandinavian Candesartan Acute Stroke Trial [NCT00120003]	Phase 3	2,500 participants (Anticipated)	Interventional	2005-06-30	Completed
Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis - Effect of Blockade of the Angiotensin-II Receptor [NCT00294775]	Phase 3	140 participants (Anticipated)	Interventional	2006-02-28	Active, not recruiting
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients [NCT00125463]	Phase 3	3,200 participants	Interventional	2001-09-30	Active, not recruiting
Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation [NCT00139386]	Phase 4	1,119 participants (Actual)	Interventional	2005-10-31	Completed
[NCT00154050]		22 participants	Interventional	2004-05-31	Completed
Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study [NCT00184587]	Phase 2	40 participants (Actual)	Interventional	2005-03-31	Completed
Non-interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or add-on Therapy. [NCT00573742]		1,940 participants (Actual)	Observational	2007-09-30	Completed
Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study [NCT00430833]	Phase 2	0 participants	Interventional		Active, not recruiting
A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension [NCT02944734]	Phase 2	392 participants (Actual)	Interventional	2014-09-30	Completed
[NCT00530595]		0 participants	Interventional		Completed
Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms [NCT00400582]	Phase 4	300 participants (Anticipated)	Interventional	2006-11-30	Completed
A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate [NCT00383929]	Phase 3	1,979 participants (Actual)	Interventional	2006-09-30	Completed
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) [NCT00108706]	Phase 4	50 participants	Interventional	2004-12-31	Active, not recruiting
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
The Renin-Angiotensin System in Essential Hypertension [NCT00141583]		11 participants (Anticipated)	Interventional	2004-04-30	Terminated(stopped due to Insufficient accrual rate)
An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers [NCT01806311]	Phase 1	34 participants (Anticipated)	Interventional	2012-12-31	Completed
[NCT00130975]	Phase 3	200 participants	Interventional	2001-04-30	Completed
Danish Hypertension Prevention Project [NCT00150631]	Phase 3	100 participants (Actual)	Interventional	2000-11-30	Active, not recruiting
A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period. [NCT00244621]	Phase 3	95 participants (Actual)	Interventional	2004-11-30	Completed
Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function [NCT01678794]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2012-02-29	Completed
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study [NCT00235287]	Phase 4	60 participants (Anticipated)	Interventional	2005-09-30	Recruiting
A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY) [NCT00227318]	Phase 3	1,000 participants	Interventional	1998-07-31	Completed
A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System [NCT00288717]		300 participants	Interventional	2006-02-28	Recruiting
Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study [NCT00320970]		36 participants	Interventional	2002-08-31	Completed
Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury [NCT05826912]	Phase 2	672 participants (Anticipated)	Interventional	2024-03-29	Not yet recruiting
Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB [NCT00328302]	Phase 4	13 participants	Interventional	2000-09-30	Active, not recruiting
Effects of Sodium Intake on Pharmacokinetic/Pharmacodynamic Relationship of a Single Dose of a Renin Angiotensin System-Blocker, or a Beta-Blocker in Normotensive Sodium-Depleted or Replated Volunteers in a Cross-Over Study [NCT00310778]	Phase 1	64 participants (Actual)	Interventional	2006-03-31	Completed
[NCT01629225]	Phase 4	500 participants (Anticipated)	Interventional	2013-07-31	Recruiting
Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial. [NCT01734096]	Phase 4	78 participants (Actual)	Interventional	2009-05-31	Completed
Renin-Angiotensin-System Quantification in Patients Treated With Aliskiren or Candesartan (RASQAL) [NCT01827202]	Phase 4	24 participants (Actual)	Interventional	2012-12-31	Completed
Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate in Healthy Male Volunteers. [NCT01845272]	Phase 1	40 participants (Anticipated)	Interventional	2013-04-30	Active, not recruiting
A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2) [NCT04351724]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2020-04-16	Recruiting
Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression [NCT01794455]	Phase 4	1 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Enrollment difficulties)
The Effect of Multidisciplinary Intervention on Patients With Persistent Post-traumatic Headache [NCT05328635]		100 participants (Anticipated)	Observational	2021-09-01	Recruiting
A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2 Study to Evaluate the Dose-response Relationship of the Efficacy and Safety of Oral Administration of TAK-272 in Patients With Type 2 Diabetes Mellitus and Mi [NCT02332824]	Phase 2	415 participants (Actual)	Interventional	2014-10-16	Completed
An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers. [NCT02988362]	Phase 1	40 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Adiposity and Endothelin Receptor Function [NCT03583866]	Early Phase 1	25 participants (Actual)	Interventional	2018-05-21	Active, not recruiting
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol [NCT01434134]	Phase 2	130 participants (Actual)	Interventional	2011-09-30	Completed
Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension [NCT01444833]		35 participants (Anticipated)	Interventional	2008-10-31	Recruiting
An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 [NCT05122182]	Phase 2	49 participants (Actual)	Interventional	2022-01-07	Terminated(stopped due to Withdrawal of funding support from the trial funder.)
Candesartan for Migraine Prevention: A Multicentre, Binational, Triple Blind, Placebo Controlled, Parallel Group Study of Two Doses of Candesartan (8 and 16 mg) [NCT04574713]	Phase 2	450 participants (Anticipated)	Interventional	2020-04-26	Recruiting
"Unisia Combination Tablets LD, HD Special Drug Use Surveillance Hypertension: Long-Term Use" [NCT02068495]		3,409 participants (Actual)	Observational	2010-06-15	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combina [NCT00360178]	Phase 3	198 participants (Actual)	Interventional	2006-07-31	Completed
An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence [NCT01062451]	Phase 1	80 participants (Actual)	Interventional	2009-05-31	Completed
Strain-based vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention Strategy in Patients With Breast Cancer Who Treated With Adjuvant Trastuzumab [NCT04429633]		136 participants (Anticipated)	Interventional	2019-07-19	Recruiting
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial [NCT01611077]	Phase 4	88 participants (Actual)	Interventional	2012-01-31	Completed
Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial [NCT01613209]	Phase 3	83 participants (Actual)	Interventional	2011-12-31	Completed
"A Randomized, Double Blind, Cross-Over, Placebo-Controlled Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism, of Non Diabetic, Non Hypertensive Subjects With Dysglycemia and Abdominal Obesity.ARAMIA" [NCT00319202]	Phase 4	56 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Difficulties in completing the required sample size)
"Early Treatment With Candesartan vs Placebo in Asymptomatic Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)" [NCT05321875]	Phase 3	320 participants (Anticipated)	Interventional	2022-06-02	Recruiting
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX) [NCT01984164]	Phase 2	176 participants (Actual)	Interventional	2014-08-20	Completed
ECARD Combination Tablets LD&HD Special Drug Use Surveillance: Long-term Use (12 Months) [NCT02016183]		3,222 participants (Actual)	Observational	2009-04-01	Completed
Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients [NCT00356395]	Phase 4	40 participants	Interventional	2003-08-31	Completed
[NCT00360763]	Phase 4	600 participants	Interventional		Recruiting
A Pilot, Proof of Concept, Placebo-controlled Trial of Candesartan as an Adjunctive Treatment for Bipolar Depression [NCT04430959]	Early Phase 1	0 participants (Actual)	Interventional	2020-10-01	Withdrawn(stopped due to The reason the study was withdrawn was due to lack of funds. In addition, the PI is moving to a different institution and it would not be feasible to proceed with the study under these circumstances.)
An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers [NCT01926652]	Phase 1	34 participants (Actual)	Interventional	2013-07-31	Completed
The RAS, Fibrinolysis and Cardiopulmonary Bypass [NCT00607672]	Phase 4	111 participants (Actual)	Interventional	2006-08-31	Completed
Pilot Study, Single-blind, Candesartan Versus Usual Care of Peripheral Neuropathy Development Induced by Vincristine (PNIV) in Patients Treated for Lymphoma B [NCT03688633]	Phase 2	9 participants (Actual)	Interventional	2019-05-01	Terminated(stopped due to Patient Recruitment Failure)
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial) [NCT00605072]	Phase 2	53 participants (Actual)	Interventional	2008-01-31	Completed
Pilot Study of Candesartan: An Angiotensin Receptor Blocker as a Treatment for Cocaine Dependence [NCT01938664]	Phase 2	30 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Results of interim efficacy analysis showed results were not promising.)
A Randomised, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Oral Doses of Candesartan Cilexetil in Healthy Subjects [NCT01976572]	Phase 1	18 participants (Actual)	Interventional	2013-10-31	Completed
"Candesartan Cilexetil Tablets Specified Drug-use Survey Hypertension: Survey on Patients With Metabolic Syndrome" [NCT02166697]		14,151 participants (Actual)	Observational	2006-06-30	Completed
Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects With Moderate to Severe Essential Hypertension [NCT01788358]	Phase 3	508 participants (Actual)	Interventional	2013-02-14	Completed
Blopress Tablets Special Drug Use Surveillance 「Challenge - Quality Control」 [NCT02211638]		18,113 participants (Actual)	Observational	2011-06-13	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00081731 (7) [back to overview]	Stroke
NCT00081731 (7) [back to overview]	Hospitalization for Congestive Heart Failure
NCT00081731 (7) [back to overview]	Need for Renal Replacement Therapy
NCT00081731 (7) [back to overview]	Myocardial Infarction
NCT00081731 (7) [back to overview]	30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days
NCT00081731 (7) [back to overview]	Cardiovascular or Renal Death
NCT00081731 (7) [back to overview]	Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy
NCT00244621 (4) [back to overview]	Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP)
NCT00244621 (4) [back to overview]	Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28
NCT00244621 (4) [back to overview]	Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28
NCT00244621 (4) [back to overview]	Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)
NCT00252694 (4) [back to overview]	Number of Participants With at Least a 3 Step Improvement or a Persistent 2-step Improvement in the ETDRS Severity Scale.
NCT00252694 (4) [back to overview]	Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale
NCT00252694 (4) [back to overview]	Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).
NCT00252694 (4) [back to overview]	Rate of Change in Urinary Albumin Excretion Rate (UAER).
NCT00252720 (4) [back to overview]	Number of Participants With a Regression of Diabetic Retinopathy.
NCT00252720 (4) [back to overview]	Rate of Change in Urinary Albumin Excretion Rate (UAER).
NCT00252720 (4) [back to overview]	Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale
NCT00252720 (4) [back to overview]	Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).
NCT00252733 (2) [back to overview]	Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.
NCT00252733 (2) [back to overview]	Rate of Change in Urinary Albumin Excretion Rate (UAER).
NCT00348686 (6) [back to overview]	Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only
NCT00348686 (6) [back to overview]	Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine
NCT00348686 (6) [back to overview]	Percent Change of B Type Natriuretic Peptides (BNP) Level
NCT00348686 (6) [back to overview]	LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index
NCT00348686 (6) [back to overview]	Change of Systolic Blood Pressure (SBP)
NCT00348686 (6) [back to overview]	Change of Diastolic Blood Pressure (DBP)
NCT00434967 (3) [back to overview]	The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study
NCT00434967 (3) [back to overview]	Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks)
NCT00434967 (3) [back to overview]	Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).
NCT00573430 (5) [back to overview]	Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation
NCT00573430 (5) [back to overview]	Inflammatory Marker (Hs-C-peptide Reactive Protein)
NCT00573430 (5) [back to overview]	The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks
NCT00573430 (5) [back to overview]	Treatment-emergent Adverse Events
NCT00573430 (5) [back to overview]	Change of Systolic and Diastolic Blood Pressure From Baseline
NCT00605072 (5) [back to overview]	Cognitive Assessment: Trail Making Test Part B
NCT00605072 (5) [back to overview]	Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall
NCT00605072 (5) [back to overview]	Cognitive Assessment: Forward Digit Span Test
NCT00605072 (5) [back to overview]	Blood Pressure Outcome: Systolic BP
NCT00605072 (5) [back to overview]	Blood Flow Velocity, Sitting
NCT00607672 (13) [back to overview]	Re-exploration for Bleeding
NCT00607672 (13) [back to overview]	New Onset Atrial Fibrillation
NCT00607672 (13) [back to overview]	Length of Hospital Stay
NCT00607672 (13) [back to overview]	Blood Loss
NCT00607672 (13) [back to overview]	Acute Kidney Injury
NCT00607672 (13) [back to overview]	Vasopressor Drug Use
NCT00607672 (13) [back to overview]	Tissue-type Plasminogen Activator (t-PA) Antigen Response
NCT00607672 (13) [back to overview]	Plasminogen Activator Inhibitor-1 (PAI-1) Response
NCT00607672 (13) [back to overview]	Interleukin-8 (IL-8) Response
NCT00607672 (13) [back to overview]	Interleukin-6 (IL-6) Response
NCT00607672 (13) [back to overview]	Interleukin-10 (IL-10) Response
NCT00607672 (13) [back to overview]	Stroke
NCT00607672 (13) [back to overview]	Blood Product Transfusion Requirement
NCT00621153 (1) [back to overview]	Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy
NCT00690612 (2) [back to overview]	Mean Change From Baseline to Final Visit in Diastolic Blood Pressure (DBP).
NCT00690612 (2) [back to overview]	Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP).
NCT00867490 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Pressure During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Rate During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Sitting Pulse Rate During the Extension Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
NCT00867490 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
NCT01025843 (4) [back to overview]	Area Under the Plasma Concentration Versus Time Curve (AUC 0-infinity) of MK-5478 and Candesartan
NCT01025843 (4) [back to overview]	Maximum Plasma Concentration (Cmax) of MK-5478 and Candesartan
NCT01025843 (4) [back to overview]	Number of Participants Who Discontinued Treatment Due to an AE
NCT01025843 (4) [back to overview]	Number of Participants With One or More Adverse Events (AEs)
NCT01052272 (7) [back to overview]	Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA)
NCT01052272 (7) [back to overview]	Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA)
NCT01052272 (7) [back to overview]	Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV)
NCT01052272 (7) [back to overview]	Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness)
NCT01052272 (7) [back to overview]	LV End Systolic Maximum Shortening (LVES Max Shortening)
NCT01052272 (7) [back to overview]	Peak Early Filling Rate Normalized to EDV
NCT01052272 (7) [back to overview]	Left Ventricular Ejection Fraction (LVEF)
NCT01678794 (2) [back to overview]	Change in Urinary Sodium Excretion
NCT01678794 (2) [back to overview]	Change in Glomerular Filtration Rate
NCT01788358 (9) [back to overview]	Number of Subjects With Clinically Relevant Changes in Laboratory Parameters
NCT01788358 (9) [back to overview]	Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 52/End of Study (EOS)
NCT01788358 (9) [back to overview]	Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28
NCT01788358 (9) [back to overview]	Change From Baseline In Mean Seated Systolic Blood Pressure (MSSBP) At Weeks 28 And 52
NCT01788358 (9) [back to overview]	Change From Baseline in Mean Seated Diastolic Blood Pressure (MSDBP) at Weeks 28 and 52
NCT01788358 (9) [back to overview]	Blood Pressure Response Rate at Weeks 28 and 52
NCT01788358 (9) [back to overview]	Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 28
NCT01788358 (9) [back to overview]	Blood Pressure Control Rate at Weeks 28 and 52
NCT01788358 (9) [back to overview]	Number of Subjects With Treatment-emergent Adverse Events (TEAEs) of Special Interest up to Week 52/End of Study (EOS)
NCT01794455 (2) [back to overview]	Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16)
NCT01794455 (2) [back to overview]	Montgomery-Asberg Depression Rating Scale
NCT01938664 (3) [back to overview]	# of Participants Retained in Study
NCT01938664 (3) [back to overview]	# of Participants With Presence of Cocaine Metabolites Via Urinalysis
NCT01938664 (3) [back to overview]	# of Participants With Adverse Events
NCT01976572 (4) [back to overview]	T1/2
NCT01976572 (4) [back to overview]	Cmax of Candesartan
NCT01976572 (4) [back to overview]	AUC0-t of Candesartan
NCT01976572 (4) [back to overview]	Tmax
NCT01984164 (8) [back to overview]	Memory
NCT01984164 (8) [back to overview]	Attention Measured Using Digit Span Backward
NCT01984164 (8) [back to overview]	Attention Measured Using Digit Span Forward
NCT01984164 (8) [back to overview]	Cerebral Perfusion
NCT01984164 (8) [back to overview]	Language
NCT01984164 (8) [back to overview]	Executive Function
NCT01984164 (8) [back to overview]	"NINDS-initiated EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or EXAMINER Tool Box."
NCT01984164 (8) [back to overview]	White Matter Lesion Volume
NCT02016183 (4) [back to overview]	Changes From Baseline in Systolic Blood Pressure (SBP) at Each Time Point
NCT02016183 (4) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)
NCT02016183 (4) [back to overview]	Changes From Baseline in Diastolic Blood Pressure (DBP) at Each Time Point
NCT02016183 (4) [back to overview]	Changes From Baseline in Pulse Rate at Each Time Point
NCT02068495 (6) [back to overview]	Changes From Baseline in Diastolic Blood Pressure (DBP) at Final Assessment
NCT02068495 (6) [back to overview]	Changes From Baseline in Pulse Rate at Final Assessment
NCT02068495 (6) [back to overview]	Changes From Baseline in Systolic Blood Pressure (SBP) at Final Assessment
NCT02068495 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)
NCT02068495 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Events
NCT02068495 (6) [back to overview]	Percentage of Participants Who Meet Targeted Blood Pressure Level at Baseline and Final Assessment
NCT02166697 (6) [back to overview]	Number of Participants Reporting One or More Adverse Drug Reactions (ADR)
NCT02166697 (6) [back to overview]	Number of Participants Reporting One or More Serious Adverse Drug Reactions (SADR)
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events Affected by Underlying Risk Factors of Obesity + Blood Glucose Abnormalities + Lipid Abnormalities
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events Affected by Underlying Risk Factors of Obesity + Blood Glucose Abnormalities, Obesity + Lipid Abnormalities, or Blood Glucose Abnormalities + Lipid Abnormalities
NCT02166697 (6) [back to overview]	Incidence of Cerebrovascular/Cardiovascular Events Affected by Underlying Risk Factors of Obesity, Blood Glucose Abnormalities, or Lipid Abnormalities
NCT02211638 (6) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Continued Candesartan Therapy at Week 14
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Switched to ARB Combination Drug Therapy at Week 14
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Switched to Calcium Channel Blocker (CCB)-Containing ARB Combination Drug Therapy at Week 14
NCT02211638 (6) [back to overview]	Changes in Clinic Blood Pressure in the Sitting Position for Participants Who Switched to Diuretic-containing ARB Combination Drug Therapy at Week 14
NCT02332824 (5) [back to overview]	Urine Albumin/Creatinine Ratio (UACR) at Each Assessment Point
NCT02332824 (5) [back to overview]	Remission Rate From Early-Stage Nephropathy (Stage 2) to Pre-Nephropathy Stage (Stage 1) at the End of Treatment (Week 12)
NCT02332824 (5) [back to overview]	Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12)
NCT02332824 (5) [back to overview]	Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
NCT02332824 (5) [back to overview]	Progression Rate From Early-Stage Nephropathy (Stage 2) to Overt Nephropathy (Stage 3) During the Treatment Period (Week 12)
NCT02646982 (22) [back to overview]	Number of Participants Discontinuing Study Medication
NCT02646982 (22) [back to overview]	Number of Participants With Hyperkalemia
NCT02646982 (22) [back to overview]	Number of Participants With Elevated Serum Creatinine
NCT02646982 (22) [back to overview]	Number of Participants With a Hypotensive Episode
NCT02646982 (22) [back to overview]	EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) Toolbox Composite Score
NCT02646982 (22) [back to overview]	Trail Making Test (TMT) Part B - A
NCT02646982 (22) [back to overview]	Trail Making Test (TMT) Part B
NCT02646982 (22) [back to overview]	Pulse Wave Velocity (PWV)
NCT02646982 (22) [back to overview]	Hopkins Verbal Learning Test (HVLT) Delayed Recall Score
NCT02646982 (22) [back to overview]	Hippocampal Volume
NCT02646982 (22) [back to overview]	Global Standardized Uptake Value Ratio (SUVR) of [18F]T807
NCT02646982 (22) [back to overview]	Global Standardized Uptake Value Ratio (SUVR) of (11)C-Pittsburgh Compound B ((11)C-PiB)
NCT02646982 (22) [back to overview]	Clinical Dementia Rating (CDR) Score
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Total Tau Levels
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) of Tau Phosphorylated at Threonine 181 (p-tau181) Levels
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Amyloid Aβ42/Aβ40 Levels
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Amyloid Aβ42 Levels
NCT02646982 (22) [back to overview]	Cerebrospinal Fluid (CSF) Amyloid Aβ40 Levels
NCT02646982 (22) [back to overview]	Augmentation Index (AI)
NCT02646982 (22) [back to overview]	Vasoreactivity
NCT02646982 (22) [back to overview]	Number of Participants With Symptoms of Hypotension
NCT02646982 (22) [back to overview]	Number of Participants With Hypotensive Episodes and Symptoms
NCT03640312 (17) [back to overview]	Proportion of Patients With Adverse Event Free Hypertension Control
NCT03640312 (17) [back to overview]	Rate of Adverse Events of Special Interest
NCT03640312 (17) [back to overview]	Health-related Quality of Life
NCT03640312 (17) [back to overview]	Proportion of Patients With Hypertension Control
NCT03640312 (17) [back to overview]	Mean Diastolic Blood Pressure
NCT03640312 (17) [back to overview]	Mean Systolic Blood Pressure
NCT03640312 (17) [back to overview]	Medication Adherence
NCT03640312 (17) [back to overview]	Number of Patients Requiring Step up Treatment
NCT03640312 (17) [back to overview]	Percentage of Participants With Potentially Related Adverse Events
NCT03640312 (17) [back to overview]	Percentage of Participants With Serious Adverse Events (SAEs)
NCT03640312 (17) [back to overview]	Mean Change in Serum Sodium
NCT03640312 (17) [back to overview]	Mean Change in Serum Potassium
NCT03640312 (17) [back to overview]	Mean Change in Serum Creatinine
NCT03640312 (17) [back to overview]	Mean Change in Blood Urea Nitrogen
NCT03640312 (17) [back to overview]	Change in Mean Systolic Blood Pressure
NCT03640312 (17) [back to overview]	Change in Mean Systolic Blood Pressure
NCT03640312 (17) [back to overview]	Change in Mean Diastolic Blood Pressure

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Intervention	participants (Number)
Glycemia Trial: Intensive Control	503
Glycemia Trial: Standard Control	543

Intervention	participants (Number)
Placebo	8
Candesartan 32 mg	198
HCT 25 mg	168
Candesartan/HCT 32/25 mg	304

Intervention	mm Hg (Least Squares Mean)
Placebo	-3.7
Candesartan 32 mg	-13.1
HCT 25 mg	-11.6
Candesartan/HCT 32/25 mg	-21.4

Intervention	mm Hg (Least Squares Mean)
Placebo	-3.3
Candesartan 32 mg	-9.3
HCT 25 mg	-7.7
Candesartan/HCT 32/25 mg	-13.9

Intervention	mL/min/1.73 m2 (Mean)
Candesartan 8 mg	1.28
Candesartan 16mg	1.20
Candesartan 32mg	0.56

Intervention	mg/dL (Mean)
Candesartan 8 mg	0.01
Candesartan 16mg	-0.17
Candesartan 32mg	-0.01

Intervention	mg/g (Mean)
Candesartan 8 mg	794.0
Candesartan 16mg	639.9
Candesartan 32mg	819.0

Intervention	mmHg (Mean)
	Systolic	Diastolic
Candesartan 16mg	-13.30	-8.00
Candesartan 32mg	-16.10	-13.00
Candesartan 8 mg	-11.70	-8.90

Intervention	percentage of patients (Number)
	Dobutamine	Mlrinone	Norepinephrine	Epinephrine
Candesartan (ARB)	27.3	22.7	95.5	13.6
Placebo	35.7	25.0	85.7	7.1
Ramipril (ACEI)	29.2	25.0	79.2	4.3

Intervention	ng/mL (Mean)
	Pre CPB	60min of CPB	Post surgery	Postoperative day 1	Postoperative day 2
Candesartan (ARB)	11.97	24.89	31.47	15.75	12.89
Placebo	14.36	27.65	34.56	20.25	16.56
Ramipril (ACEI)	14.05	36.67	41.11	17.10	12.49

Intervention	percentage of patients (Number)
	Packed red blood cells	Plasma	Platelets	Cryoprecipitate
Candesartan (ARB)	2.7	31.8	22.7	4.5
Placebo	67.9	60.7	46.4	7.1
Ramipril (ACEI)	62.5	29.2	29.2	4.2

Intervention	mm Hg (Mean)
Atacand .05 mg	-6.0
Atacand .20 mg	-8.9
Atacand .40 mg	-12.0

Intervention	Percent change (Median)
Atacand .05 mg	-11.1
Atacand .20 mg	-40.6
Atacand .40 mg	-50.0

Intervention	mmHg (Least Squares Mean)
Candesartan Cilexetil/Hydroclorozide Combination Therapy	-17.0
Candesartan Cilexetil Monotherapy	-14.1

Intervention	Percentage of patients (Number)
	msSBP response	msDBP response
Phase 2 - Aliskiren+HCTZ	37.4	34.1

Intervention	Percentage of patients (Number)
	msSBP response	msDBP response
Phase III - Aliskiren+HCTZ+Amlodipine	54.1	47.5

Intervention	Percentage of patients (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Phase 2 - Aliskiren+HCTZ	37.4	33.3

Intervention	umol.hr/L (Mean)
MK-5478 1 mg	0.236
MK-5478 2 mg	0.494
MK-5478 5 mg	1.87
MK-5478 8 mg	1.80
MK-5478 12 mg	1.36
MK-5478 18 mg	2.23
MK-5478 24 mg	3.15
MK-5478 38 mg	4.50
MK-5478 2 mg - Fed	0.504
Candesartan 32 mg	5.89
Candesartan 32 mg - Fed	4.46

Intervention	µmol/L (Mean)
MK-5478 1 mg	0.0291
MK-5478 2 mg	0.0573
MK-5478 5 mg	0.254
MK-5478 8 mg	0.227
MK-5478 12 mg	0.120
MK-5478 18 mg	0.245
MK-5478 24 mg	0.321
MK-5478 38 mg	0.532
MK-5478 2 mg - Fed	0.0553
Candesartan 32 mg	0.476
Candesartan 32 mg - Fed	0.451

Intervention	ml/m^2 (Mean)
	Month 0 (n=17,17,18,18)	Month 6(n=14,11,11,12)	Month 9(n=1,2,0,0)	Month12(n=12,11,11,11)	Month 15(n=3,2,1,1)	Month 18(n=10,12,8,8)	Month 21(n=3,0,0,1)	Month 24 (n=11,9,8,10)	Month 27 (n=1,1,0,1)
Candesartan Cilexetil	78.06	78.60	93.57	85.44	90.20	82.74	NA	84.28	76.65
Candesartan Cilexetil and Allopurinol	79.03	78.01	NA	79.75	63.1	84.95	75.27	79.72	75.05
Ramipril	73.03	74.10	73.23	75.34	81.19	75.28	71.99	70.46	48.68
Ramipril and Allopurinol	78.52	86.13	NA	83.95	108.25	67.96	NA	71.63	NA

Intervention	percent of length at end of filling (Mean)
	Month 0 (n=17,17,17,18)	Month 6(n=14,11,10,12)	Month 9(n=1,2,0,0)	Month 12(n=11,11,10,10)	Month 15(n=3,2,1,1)	Month 18(n=10,12,7,8)	Month 21(n=3,0,0,1)	Month 24 (n=11,9,8,10)	Month 27 (n=1,1,0,1)
Candesartan Cilexetil	16.68	17.50	19.08	17.13	16.28	17.55	NA	16.62	20.38
Candesartan Cilexetil and Allopurinol	16.00	18.50	NA	18.51	16.36	17.52	17.89	17.85	16.59
Ramipril	15.81	16.88	18.43	14.57	17.06	17.26	16.68	15.67	13.70
Ramipril and Allopurinol	15.84	18.72	NA	17.96	14.22	17.46	NA	17.52	NA

Intervention	Subjects (Number)
	All TEAEs	Drug-related TEAEs
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	404	238

Intervention	millimeter of mercury (mmHg) (Mean)
	Baseline	Change at Week 28	Change at Week 52
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	170.7	-30.4	-30.1

candesartan cilexetil

Description

Cross-References

Synonyms (152)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (95)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (386)

Molecular Functions (122)

Ceullar Components (75)

Bioassays (138)

Research

Studies (605)

Market Indicators

Research Demand Index: 90.74

Study Types

Clinical Trials (158)

Trial Overview

Trial Outcomes

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

Death From Any Cause in the Glycemia Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Stroke in the Blood Pressure Trial.

Stroke

Hospitalization for Congestive Heart Failure

Need for Renal Replacement Therapy

Myocardial Infarction

30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days

Cardiovascular or Renal Death

Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy

Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP)

Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28

Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28

Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)

Number of Participants With at Least a 3 Step Improvement or a Persistent 2-step Improvement in the ETDRS Severity Scale.

Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale

Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).

Rate of Change in Urinary Albumin Excretion Rate (UAER).

Number of Participants With a Regression of Diabetic Retinopathy.

Rate of Change in Urinary Albumin Excretion Rate (UAER).

Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale

Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).

Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.

Rate of Change in Urinary Albumin Excretion Rate (UAER).

Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only

Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine

Percent Change of B Type Natriuretic Peptides (BNP) Level

LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index

Change of Systolic Blood Pressure (SBP)

Change of Diastolic Blood Pressure (DBP)

The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study

Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks)

Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).

Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation

Inflammatory Marker (Hs-C-peptide Reactive Protein)

The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks

Treatment-emergent Adverse Events

Change of Systolic and Diastolic Blood Pressure From Baseline

Cognitive Assessment: Trail Making Test Part B

Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall

Cognitive Assessment: Forward Digit Span Test

Blood Pressure Outcome: Systolic BP

Blood Flow Velocity, Sitting

Re-exploration for Bleeding

New Onset Atrial Fibrillation

Length of Hospital Stay

Intervention	percentage of subjects (Number)
	Week 28	Week 52
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	86.6	86.2

Intervention	Subjects (Number)
	Oedema (mild)	Oedema (moderate)	Oedema (severe)	Headache (mild)	Headache (moderate)	Flushing (mild)	Symptomatic hypotension (mild)
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	124	54	7	31	15	3	4

Intervention	Subjects (Number)
	Oedema (mild)	Oedema (moderate)	Oedema(severe)	Headache (mild)	Headache (moderate)	Flushing (mild)	Symptomatic hypotension (mild)
Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)	131	56	7	31	17	3	4

Intervention	participants (Number)
Candesartan w Cognitive Behavior Therapy	5
Placebo w Cognitive Behavior Therapy	0

Intervention	mmHg (Mean)
	Change in SBP at Month 1	Change in SBP at Month 2	Change in SBP at Month 3	Change in SBP at Month 4	Change in SBP at Month 5	Change in SBP at Month 6	Change in SBP at Month 7	Change in SBP at Month 8	Change in SBP at Month 9	Change in SBP at Month 10	Change in SBP at Month 11	Change in SBP at Month 12	Change in SBP at Final
Candesartan Cilexetil/Hydrochlorothiazide	-13.3	-14.8	-15.4	-15.7	-15.6	-16.1	-15.8	-15.8	-16.4	-16.6	-17.0	-18.1	-17.5

Intervention	mmHg (Mean)
	Change in DBP at Month 1	Change in DBP at Month 2	Change in DBP at Month 3	Change in DBP at Month 4	Change in DBP at Month 5	Change in DBP at Month 6	Change in DBP at Month 7	Change in DBP at Month 8	Change in DBP at Month 9	Change in DBP at Month 10	Change in DBP at Month 11	Change in DBP at Month 12	Change in DBP at Final
Candesartan Cilexetil/Hydrochlorothiazide	-6.5	-7.3	-7.6	-7.8	-7.8	-8.0	-8.1	-8.2	-8.5	-8.7	-8.5	-9.1	-8.5

Intervention	Beats per minutes (Mean)
	Change in Pulse Rate at Month 1	Change in Pulse Rate at Month 2	Change in Pulse Rate at Month 3	Change in Pulse Rate at Month 4	Change in Pulse Rate at Month 5	Change in Pulse Rate at Month 6	Change in Pulse Rate at Month 7	Change in Pulse Rate at Month 8	Change in Pulse Rate at Month 9	Change in Pulse Rate at Month 10	Change in Pulse Rate at Month 11	Change in Pulse Rate at Month 12	Change in Pulse Rate at Final assessment
Candesartan Cilexetil/Hydrochlorothiazide	-1.3	-1.1	-1.3	-1.5	-1.3	-1.5	-1.1	-1.5	-1.6	-1.7	-1.5	-1.8	-1.6

Intervention	Percentage of Participants (Number)
	Baseline	Final Assessment
Candesartan Cilexetil/Amlodipine	28.5	66.9

Intervention	Number of events per 1,000 person-years (Number)
	Sudden Death	Cerebral Hemorrhage	Cerebral Infarction	Subarachnoid Hemorrhage	Acute Myocardial Infarction	Hospitalization for Heart Failure	Intervention/Hospitalization for Angina Pectoris	Atrial Fibrillation	Transition to Dialysis	Renal Transplant	Dissecting Aortic Aneurysm	Diabetic Retinopathy	New-Onset Diabetes	Primary MACE	Primary MACE 2	Renal Events
Candesartan Cilexetil	0.24	0.57	2.34	0.15	0.99	0.27	1.74	1.35	0.30	0.00	0.06	0.15	4.35	4.29	6.29	0.30

Intervention	mmHg (Mean)
	Month 3, SBP	Last Dose of Candesartan, SBP	Month 3, DBP	Last Dose of Candesartan, DBP
Candesartan Cilexetil 4 mg to 8 mg	-20.1	-18.1	-10.4	-9.3